喘息・COPDと気道疾患包括診療マニュアル

出版社： 中外医学社
著者：
発行日： 2023-04-30
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784498131040
電子書籍版： 2023-04-30 （1版1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：4～8営業日

5,940 円(税込)

購入する
電子書籍
章別単位で購入
ブラウザ、アプリ閲覧

5,940 円(税込)

購入する

商品紹介

喘息・COPDなど非常にcommonなのに診療に悩む気道疾患についてプライマリケアに必要な禁煙指導，吸入療法から高度専門的治療まで実践的知識が身につく1冊．
最新のガイドラインを網羅するだけでなく，診療最前線にいるエキスパートたちの現場でのコツや勘所など，実際に役立つ情報をわかりやすくまとめた便利なマニュアル．

目次

  • I　気道疾患診療の基本ポイント
    　1　気道疾患の包括的診療アプローチの重要性
    　2　気道疾患診療で行うことが望ましい血液検査
    　3　呼吸機能および呼気ガス検査

    II　気道疾患診療に必要な管理と治療
    　1　環境整備指導の実際
    　2　禁煙指導（支援）の実際
    　3　気管支拡張薬の選び方と用い方
    　4　吸入ステロイド薬および各種配合剤の選び方と使い方
    　5　吸入指導の実際
    　6　去痰薬・鎮咳薬の選び方・用い方
    　7　マクロライド少量長期療法
    　8　呼吸リハビリテーション指導の実際
    　9　生物学的製剤と気管支熱形成術
    　10　喘息でのアレルゲン免疫療法
    　11　高齢者指導のポイント

    III　各種気道疾患と診療のポイント
    　1　慢性気道疾患患者における急性気道感染とその対応
    　2　慢性咳嗽
    　3　喘息（成人）
    　4　喘息（小児～学童）
    　5　COPD
    　6　COPDと喘息の合併
    　7　アレルギー性気管支肺真菌症
    　8　気管支拡張症
    　9　副鼻腔気管支症候群とびまん性汎細気管支炎
    　10　好酸球性多発血管炎性肉芽腫症
    　11　リウマチ・膠原病の気道病変
    　12　閉塞性細気管支炎とリンパ脈管筋腫症

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I 気道疾患診療の基本ポイント

P.8 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン第6版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2022[第6版]. 東京: メディカルレビュー社. 2022.
 
2) 永田 真, 編著. アレルギー診療必携ハンドブック. 東京: 中外医学社; 2021.
 
3) 日本アレルギー学会. 皮膚テストの手引き. 2021.
 
4) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 喘息予防・管理ガイドライン2021.東京: 協和企画; 2021.
 
5) 日本アレルギー学会「アレルゲン免疫療法の手引き」作成委員会. アレルゲン免疫療法の手引き. 東京: 協和企画; 2022.
 
P.18 掲載の参考文献
1) O'Sullivan JA, Bochner BS. Eosinophils and eosinophil-associated diseases: An update. J Allergy Clin Immunol. 2018; 141: 505-17.
PubMed
2) Malinovschi A, Fonseca JA, Jacinto T, et al. Exhaled nitric oxide levels and blood eosinophil counts independently associate with wheeze and asthma events in National Health and Nutrition Examination Survey subjects. J Allergy Clin Immunol. 2013; 132: 821-7.e1-5.
 
3) Li JH, Han R, Wang YB, et al. Diagnostic possibility of the combination of exhaled nitric oxide and blood eosinophil count for eosinophilic asthma. BMC Pulm Med. 2021; 21: 259.
PubMed
4) Soma T, Iemura H, Naito E et al. Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma. Allergol Int. 2018; 67S: S3-11.
PubMed
5) 日本喘息学会. 喘息診療実践ガイドライン2022.東京: 協和企画; 2022.
 
6) Lau S, Illi S, Sommerfeld C, et al. Early exposure to house-dust mite and cat allergens and development of childhood asthma: a cohort study. Multicentre Allergy Study Group. Lancet. 2000; 356: 1392-7.
 
7) Jaakkola MS, Ieromnimon A, Jaakkola JJ. Are atopy and specific IgE to mites and molds important for adult asthma? J Allergy Clin Immunol. 2006; 117: 642-8.
 
8) 足立 満, 井上洋西, 田村 弦, 他. 成人気管支喘息における感作アレルゲンの全国調査. アレルギー・免疫. 2006; 13, 548-54.
 
9) Siroux V, Oryszczyn MP, Paty E, et al. Relationships of allergic sensitization, total immunoglobulin E and blood eosinophils to asthma severity in children of the EGEA Study. Clin Exp Allergy 2003, 33: 746-51.
PubMed
10) Moore WC, Bleecker ER, Curran-Everett D, et al. Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119: 405-13.
PubMed
11) Patelis A, Janson C, Borres MP, et al. Aeroallergen and food IgE sensitization and local and systemic inflammation in asthma. Allergy. 2014; 69: 380-7.
PubMed
12) Tanaka A, Jinno M, Hirai K, et al. Longitudinal increase in total IgE levels in patients with adult asthma: an association with poor asthma control. Respir Res. 2014; 15: 144.
PubMed
13) 浅野浩一郎. アレルギー性気管支肺真菌症の診療の手引き. アレルギー. 2020; 69: 164-8.
Medical*Online
14) Seyama K, Hirai T, Mishima M, et al. Respiratory Failure Research Group of the Japanese Ministry of Health, Labour, and Welfare. A nationwide epidemiological survey of alpha1-antitrypsin deficiency in Japan. Respir Investig. 2016; 54: 201-6.
 
15) 日本呼吸器学会. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第6版. 東京: メディカルレビュー社; 2022.
 
16) Pascoe S, Locantore N, Dransfield MT, et al. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015; 3: 435-42.
 
17) Global Initiative for Chronic Obstructive Lung Disease 2022 Report. <https://goldcopd.org>
 
18) Shibata Y, Horita N, Yamamoto M, et al. Diagnostic test accuracy of anti-glycopeptidolipid-core IgA antibodies for Mycobacterium avium complex pulmonary disease: systematic review and meta-analysis. Sci Rep. 2016; 6: 29325.
PubMed
19) 藤田清貴. 寒冷凝集反応および慣例で反応するタンパク質について. 体外循環技術. 2006; 33: 1-7.
 
P.28 掲載の参考文献
1) Shaw DE, Berry MA, Thomas M, et al. The use of exhaled nitric oxide to guide asthma management: a randomized controlled trial. Am J Respir Crit Care Med. 2007; 176: 231-7.
PubMed
2) ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005.Am J Respir Crit Care Med. 2005; 171: 912-30.
PubMed
3) 平野綱彦, 一ノ瀬正和. 【呼吸器疾患治療の新しい展開】 慢性閉塞性肺疾患(COPD)薬物治療. 医学と薬学. 2005; 54: 441-8.
 
4) Ichinose M, Sugiura H, Yamagata S, et al. Increase in reactive nitrogen species production in chronic obstructive pulmonary disease airways. Am J Respir Crit Care Med. 2000; 162(2 Pt 1): 701-6.
 
5) Hemmingsson T, Linnarsson D, Gambert R. Novel hand-held device for exhaled nitric oxide-analysis in research and clinical applications. J Clin Monit Comput. 2004; 18(5-6): 379-87.
 
6) Pizzimenti S, Bugiani M, Piccioni P, et al. Exhaled nitric oxide measurements: correction equation to compare hand-held device to stationary analyzer. Respir Med. 2008; 102: 1272-5.
PubMed
7) Matsunaga K, Hirano T, Kawayama T, et al. Reference ranges for exhaled nitric oxide fraction in healthy Japanese adult population. Allergol Int. 2010; 59: 363-7.
PubMed
8) Matsunaga K, Hirano T, Akamatsu K, et al. Exhaled nitric oxide cutoff values for asthma diagnosis according to rhinitis and smoking status in Japanese subjects. Allergol Int. 2011; 60: 331-7.
PubMed
9) Ichinose M, Takahashi T, Sugiura H, et al. Baseline airway hyperresponsiveness and its reversible component: role of airway inflammation and airway calibre. Eur Respir J. 2000; 15: 248-53.
PubMed
10) McNicholl DM, Stevenson M, McGarvey LP, et al. The utility of fractional exhaled nitric oxide suppression in the identification of nonadherence in difficult asthma. Am J Respir Crit Care Med. 2012; 186: 1102-8.
PubMed
11) Bates CA, Silkoff PE. Exhaled nitric oxide in asthma: from bench to bedside. J Allergy Clin Immunol. 2003; 111: 256-62.
PubMed
12) Hayata A, Matsunaga K, Hirano T, et al. Stratifying a risk for an increased variation of airway caliber among the clinically stable asthma. Allergol Int. 2013; 62: 343-9.
PubMed
13) Matsunaga K, Yanagisawa S, Hirano T, et al. Associated demographics of persistent exhaled nitric oxide elevation in treated asthmatics. Clin Exp Allergy. 2012; 42: 775-81.
PubMed
14) Matsunaga K, Hirano T, Oka A, et al. Persistently high exhaled nitric oxide and loss of lung function in controlled asthma. Allergo Int. 2016; 65: 266-71.
 
15) Sugiura H, Komaki Y, Koarai A, et al. Nitrative stress in refractory asthma. J Allergy Clin Immunol. 2008; 121: 355-60.
PubMed
16) Matsunaga K, Hirano T, Akamatsu K, et al. Predictors for identifying the efficacy of systemic steroids on sustained exhaled nitric oxide elevation in severe asthma. Allergol Int. 2013; 62: 359-65.
PubMed
17) Mansur AH, Srivastava S, Sahal A. Disconnect of type 2 biomarkers in severe asthma; dominated by FeNO as a predictor of exacerbations and periostin as predictor of reduced lung function. Respir Med. 2018; 143: 31-8.
PubMed
18) Lim CS, Rani FA, Tan LE. Response of exhaled nitric oxide to inhaled corticosteroids in patients with stable COPD: A systematic review and meta-analysis. Clin Respir Jl. 2016.
 
19) Akamatsu K, Matsunaga K, Sugiura H, et al. Improvement of airflow limitation by fluticasone propionate/salmeterol in chronic obstructive pulmonary disease: What is the specific marker? Front Pharmacol. 2011; 2: 36.
PubMed
20) Alcazar-Navarrete B, Romero-Palacios PJ, Ruiz-Sancho A, et al. Diagnostic performance of the measurement of nitric oxide in exhaled air in the diagnosis of COPD phenotypes. Nitric Oxide. 2016; 54: 67-72.
 
21) Arnold RJG, Layton A, Massanari M. Cost impact of monitoring exhaled nitric oxide in asthma management. Allergy Asthma Proc. 2018; 39: 338-44.
PubMed
22) Lee JE, Rhee CK, Lim JH, et al. Fraction of exhaled nitric oxide in patients with acute eosinophilic pneumonia. Chest. 2012; 141: 1267-72.
PubMed
23) 末竹諒 大, 上原 翔, 濱田和希, 他. 呼気NO濃度の経時的な測定が診断・病勢評価に有用であった急性好酸球性肺炎の19歳男性例. 第57回日本呼吸器学会中国・四国地方会, 高知市. 2017.
 

II 気道疾患診療に必要な管理と治療

P.42 掲載の参考文献
1) Salo PM, Cohn RD, Zeldin DC. Bedroom allergen exposure beyond house dust mites. Curr Allergy Asthma Rep. 2018; 18: 52.
PubMed
2) Mendy A, Wilkerson J, Salo PM, et al. Exposure and sensitization to pets modify endotoxin association with asthma and wheeze. J Allergy Clin Immunol Pract. 2018; 6: 2006-13.e4.
 
3) 福冨友馬. 真菌とアレルギー疾患. アレルギー. 2016; 65: 113-7.
Medical*Online
4) Mungan D, Bavbek S, Peksari V, et al. Trichophyton sensitivity in allergic and nonallergic asthma. Allergy. 2001; 56: 558-62.
PubMed
5) Thorne PS, Mendy A, Metwali N, et al. Endotoxin exposure: predictors and prevalence of associated asthma outcomes in the United States. Am J Respir Crit Care Med. 2015; 192: 1287-97.
PubMed
6) Wang J, Pindus M, Janson C, et al. Dampness, mould, onset and remission of adult respiratory symptoms, asthma and rhinitis. Eur Respir J. 2019; 53: 1801921.
PubMed
7) Caillaud D, Leynaert B, Keirsbulck M, et al. Indoor mould exposure, asthma and rhinitis: findings from systematic reviews and recent longitudinal studies. Eur Respir Rev. 2018; 27: 170137.
PubMed
8) Fairs A, Agbetile J, Hargadon B, et al. IgE sensitization to Aspergillus fumigatus is associated with reduced lung function in asthma. Am J Respir Crit Care Med. 2010; 182: 1362-8.
PubMed
9) Matsuoka H, Niimi A, Matsumoto H, et al. Specific IgE response to Trichophyton and asthma severity. Chest 2009; 135: 898-903.
PubMed
10) Wise F, Sulzberger MB. Urticaria and hay fever due to Trichophyton. JAMA. 1930; 95: 1504-8.
 
11) 星 理恵, 中込一之, 青木 洋敏, 他. トリコフィトンの職業性曝露が増悪の原因と考えられた気管支喘息の一家. アレルギー. 2011; 60: 207-13.
 
12) 杣 知行. 環境因子中エンドトキシンとアレルギー. アレルギー・免疫. 2017; 24: 32-40
 
13) 喘息予防・管理ガイドライン2021作成委員会. 増悪の危険因子とその予防. In: 日本アレルギー学会喘息ガイドライン専門部会, 編. 喘息予防・管理ガイドライン 2021. 東京: 協和企画; 2021. p.39-41.
 
14) 黒澤 一. 危険因子. In: 日本呼吸器学会COPD ガイドライン第5版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第5版. 東京: メディカルレビュー社; 2018. p.18-9.
 
15) Tovey ER, Willenborg CM, Crisafulli DA, et al. Most personal exposure to house dust mite aeroallergen occurs during the day. PLoS One. 2013; 8: e69900.
PubMed
16) Simpson A, Brough HA, Haider S, et al. Early-life inhalant allergen exposure, filaggrin genotype, and the development of sensitization from infancy to adolescence. J Allergy Clin Immunol. 2020; 145: 993-1001.
PubMed
17) Nishioka K, Yasueda H, Saito H. Preventive effect of bedding encasement with microfine fibers on mite sensitization. J Allergy Clin Immunol. 1998; 101: 28-32.
PubMed
18) Nishioka K, Saito A, Akiyama K, et al. Effect of home environment control on children with atopic or non-atopic asthma. Allergol Int. 2006; 55: 141-8.
PubMed
19) 独立行政法人環境再生保全機構<https://www.erca.go.jp/yobou/zensoku/basic/adult/knowledge/causes.html>
 
20) Shirai T, Matsui T, Suzuki K, et al. Effect of pet removal on pet allergic asthma. Chest. 2005; 127: 1565-71.
PubMed
21) Kalayci O, Miligkos M, Fireth C, et al. The role of environmental allergen control in the management of asthma. World Allergy Organ J. 2022; 15: 100634.
 
22) Sauni R, Uitti J, Jauhiainen M, et al. Remediating buildings damaged by dampness and mould for preventing or reducing respiratory tract symptoms, infections and asthma. Coohrane Database Syst Rev. 2011.CDOO7897.
 
23) Asano K, Hebisawa A, Ishiguro T, et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021; 147: 1261-8.e5.
 
P.52 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン第6版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2022[第6版]. 東京: メディカルレビュー社; 2022.
 
2) Fowler CD, Lu Q, Johnson PM, et al. Habenular α5 nicotinic receptor subunit signalling controls nicotine intake. Nature. 2011; 471: 597-601.
 
3) Thomson NC, Chaudhuri R, Livingston E. Asthma and cigarette smoking. Eur Respir J. 2004; 24: 822-33.
PubMed
4) Silva GE, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004; 126: 59-65.
 
5) 日本禁煙学会, 編. 禁煙学 改訂第4版. 東京: 南山堂; 2019.
 
6) Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for nicotine dependence: arevision of the Fagerstrom Tolerance Questionnaire. Br J Addic. 1991; 86: 1119-27.
 
7) 日本循環器学会, 日本肺癌学会, 日本癌学会, 日本呼吸器学会. 禁煙治療のための標準手順書 第8.1版. 2021年9月. <https://www.j-circ.or.jp/kinen/anti_smoke_std/pdf/anti_smoke_std_rev8_1_.pdf>
 
8) Masaki K, Tateno H, Nomura A, et al. A randomized controlled trial of a smoking cessation smartphone application with a carbon monoxide checker. NPJ Digit Med. 2020; 3: 35.
PubMed
9) 長谷 章. 禁煙外来患者に対する抑肝散加陳皮半夏のPOMS検査を用いた評価. Phil漢方 2013; No42.
 
10) 田淵貴大. 加熱式タバコの普及による喫煙状況のモニタリングおよび禁煙実施方法への影響. 厚生労働省科学研究費補助金(循環器疾患糖尿病等生活習慣病対策総合研究事業)分担研究報告書.
 
11) 田淵貴大. 新型タバコの本当のリスク アイコス, グロー, プルーム・テックの科学. 東京: 内外出版社; 2019.
 
P.67 掲載の参考文献
1) Rosethorne EM, Bradley ME, Kent TC, et al. Functional desensitization of the β 2 adrenoceptor is not dependent on agonist efficacy. Pharmacol Res Perspect. 2015; 3: e00101.
 
2) Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodeling in asthma. N Engl J Med. 2011; 364: 2006-15.
PubMed
3) 日本アレルギー学会喘息ガイドライン専門医部会「喘息予防・管理ガイドライン2021」作成委員会. In: 喘息予防・管理ガイドライン2021. 東京: 協和企画; 2021. p.97-152.
 
4) Sears MR, Taylor DR, Print CG, et al. Regular inhaled beta-agonist treatment in bronchial asthma. Lancet. 1990; 336: 1391-6.
PubMed
5) McFadden ER Jr, Gilbert IA. Exercise-induced asthma. N Engl J Med. 1994; 330: 1362-7.
PubMed
6) Kitaguchi Y, Fujimoto K, Komatsu Y, et al. Additive efficacy of short-acting bronchodilators on dynamic hyperinflation and exercise tolerance in stable COPD patients treated with long-acting bronchodilators. Respir Med. 2013; 107: 394-400.
PubMed
7) Hirano T, Matsunaga K, Hamada K, et al. Combination of assist use of short-acting beta-2 agonists inhalation and guidance based on patient-specific restrictions in daily behavior: Impact on physical activity of Japanese patients with chronic obstructive pulmonary disease. Respir Investig. 2019; 57: 133-9
 
8) Salpeter SR, Buckley NS, Ormiston TM, et al. Meta-analysis: effect of long-acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Ann Intern -Med. 2006; 144: 904-12.
PubMed
9) 日本呼吸器学会COPDガイドライン第6版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2022[第6版]. 東京: メディカルレビュー社; 2022.
 
10) Donohue JF, Betts KA, Du EX, et al. Comparative efficacy of long-acting β2-agonists as monotherapy for chronic obstructive pulmonary disease: a network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2017; 12: 367-81.
 
11) Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of -action. J Pharmacol Exp Ther. 2013; 344: 218-30.
 
12) Gosens R, Gross N. The mode of action of anticholinergics in asthma. Eur Respir J. 2018; 52: 1701247.
PubMed
13) Kirkland SW, Vandenberghe C, Voaklander B, et al. Combined inhaled beta-agonist and anticholinergic agents for emergency management in adults with asthma. Cochrane Database Syst Rev. 2017; 1: CD001284.
PubMed
14) Naline E, Grassin Delyle S, Salvator H, et al. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther. 2018; 49: 46-53.
PubMed
15) Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015; 3: 367-76.
 
16) Feldman G, Maltais F, Khindri S, et al. A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62. 5 μg compared with tiotropium 18 μg in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016; 11: 719-30.
 
17) Rheault T, Khindri S, Vahdati-Bolouri M, et al. A randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPD. ERJ Open Res. 2016; 2: 00101-2015.
PubMed
18) Beier J, Kirsten AM, Mroz R, et al. Efficacy and safety of aclidinium bromide compared with placebo and tiotropium in patients with moderate-to-severe chronic obstructive pulmonary disease: results from a 6-week, randomized, controlled Phase IIIb study. COPD. 2013; 10: 511-22.
PubMed
19) Suzuki, Sato S, Sato K, et al. Treatment efficacy of LAMA versus placebo for stable chronic obstructive pulmonary disease: A systematic review and meta-analysis. Respir Investig. 2022; 60: 108-18.
 
20) Koarai A, Sugiura H, Yamada M, et al. Treatment with LABA versus LAMA for stable COPD: a systematic review and meta-analysis. BMC Pulm Med. 2020; 20: 111.
PubMed
21) Ikeda T, Anisuzzaman AS, Yoshiki H, et al. Regional quantification of muscarinic acetylcholine receptors and β-adrenoceptors in human airways. Br J Pharmacol. 2012; 166: 1804-14.
 
22) Calzetta L, Matera MG, Cazzola M. Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol. 2018; 40: 95-103.
PubMed
23) Aziz MIA, Tan LE, Wu DB, et al. Comparative efficacy of inhaled medications(ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2018; 13: 3203-31.
 
24) Mammen MJ, Pai V, Aaron SD, et al. Dual LABA/LAMA therapy versus LABA or LAMA monotherapy for chronic obstructive pulmonary disease. A systematic review and meta-analysis in support of the American Thoracic Society clinical practice guideline. Ann Am Thorac Soc. 2020; 17: 1133-43.
PubMed
25) Hohlfeld JM, Vogel-Claussen J, Biller H, et al. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial. Lancet Respir Med. 2018; 6: 368-78.
PubMed
26) Kume H. Clinical use of β2-adrenergic receptor agonists based on their intrinsic efficacy. Allergol Int. 2005; 54: 89-97.
 
27) Yabuuchi Y, Yamashita S, Tei SS. Pharmacological studies of OPC-2009, a newly synthesized selective beta adrenoceptor stimulant, in the broncho-motor and cardiovascular system of the anesthetized dog. J Pharmacol Exp Ther. 1977; 202: 326-36.
PubMed
28) Slack RJ, Barrett VJ, Morrison VS, et al. In vitro pharmacological characterization of vilanterol, a novel long-acting β2-adrenoceptor agonist with 24-hour duration of action. J Pharmacol Exp Ther. 2013; 344: 218-30.
 
P.83 掲載の参考文献
1) 大脇 理子, 田中 明彦, 横江 琢也, 他. 気管支喘息患者の吸入流速とその規定因子に関する検討. 昭和医学会雑誌. 2011; 71: 610-5.
 
2) 長瀬 洋之. 気管支喘息のアドヒアランス改善のための実態調査-患者および薬剤師へのインターネットを利用した調査からの検討-. アレルギー・免疫, 2013; 20.
 
3) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 日本アレルギー学会喘息ガイドライン専門部会, 編. 喘息予防・管理ガイドライン2021.東京: 協和企画; 2021.
 
4) Grainge CL, Lau LC, Ward JA, et al. Effect of bronchoconstriction on airway remodelingin asthma. N Engl J Med. 2011; 364: 2006-15.
 
5) Tomlinson JE, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax. 2005; 60: 282-7.
PubMed
6) Norjavaara E, de Verdier MG. Normal pregnancy outcomes in a population-based study including 2, 968 pregnant women exposed to budesonide. J Allergy Clin Immunol. 2003; 111: 736-42.
 
7) 近藤 哲理, 谷垣 俊守, 日比野 真, 他. ドライパウダー吸入器および吸入指導用トレーナーの吸気抵抗とその臨床的意義. アレルギー. 2014; 63: 1325-9.
Medical*Online
8) Fukumitsu K, Kanemitsu Y, Asano T, et al. Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma. J Allergy Clin Immunol Pract. 2018; 6: 1613-20. e2.
 
9) Kerstjens HA, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015; 3: 367-76.
 
10) Kerstjens HA, Engel M, Dahl R, et al. Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med. 2012; 367: 1198-207.
PubMed
11) Matsunaga K, Hamada K, Oishi K, et al. Factors Associated with physician-patient discordance in the perception of asthma control. J Allergy Clin Immunol Pract. 2019; 7: 2634-41.
PubMed
12) Adachi M, Hozawa S, Nishikawa M, et al. Asthma control and quality of life in a real-life setting: a cross-sectional study of adult asthma patients in Japan(ACQUIRE-2). J Asthma. 2019; 56: 1016-25.
 
13) Ismaila AS, Huisman EL, Punekar YS, et al. Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis. Int J Chron Obstruct Pulmon Dis. 2015; 10: 2495-517.
PubMed
14) Naline E, Grassin Delyle S, et al. Comparison of the in vitro pharmacological profiles of long-acting muscarinic antagonists in human bronchus. Pulm Pharmacol Ther. 2018; 49: 46-53
 
15) Lee LA, Bailes Z, Barnes N, et al. Efficacy and safety of once-daily single-inhaler triple therapy(FF/UMEC/VI)versus FF/VI in patients with inadequately controlled asthma(CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir Med. 2021; 9: 69-84.
 
16) Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma(IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020; 8: 1000-12.
PubMed
17) Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study(ARGON). Respir Med. 2020; 170: 106021.
 
18) 日本呼吸器学会COPDガイドライン第6版作成委員会, 編. COPD診断と治療のためのガイドライン2022[第6版]. 東京: メディカルレビュー社; 2022.
 
19) Rabe KF, Martinez FJ, Ferguson GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020; 383: 35-48.
PubMed
20) Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018; 378: 1671-80.
PubMed
21) Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2020; 201: e56-69.
PubMed
22) Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-glycopyrronium versus salmeterol-fluticasone for COPD. N Engl J Med. 2016; 374: 2222-34.
PubMed
23) Ferguson GT, Rabe KF, Martinez FJ, et al. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease(KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Lancet Respir Med. 2018; 6: 747-58.
PubMed
24) Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020; 201: 1508-16.
PubMed
25) Chalmers JD, Laska IF, Franssen FME, et al. Withdrawal of inhaled corticosteroids in COPD: a European Respiratory Society guideline. Eur Respir J. 2020; 55: 200351.
 
P.97 掲載の参考文献
1) 日本喘息学会. 喘息診療実践ガイドライン2022(PGAM2022). 東京: 協和企画; 2022.
 
2) Yoshida T, Kondo R, Horiguchi T. A comparison of posterior pharyngeal wall areas between different tongue positions during inhalation. J Allergy Clin Immunol Pract. 2019; 7: 743-5. e1.
 
3) Horiguchi T, Kondo R. Determination of the preferred tongue position for optimal inhaler use. J Allergy Clin Immunol Pract. 2018; 6: 1039-41.e3.
 
4) Yokoi T, Kondo R, Horiguchi T. Residual fluticasone in the oral cavity after inhalaion with different tongue position. J Allergy Clin Immunol Pract. 2019; 7: 1668-70
 
P.108 掲載の参考文献
1) 日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会, 編. 咳嗽・喀痰の診療ガイドライン2019.東京: メディカルレビュー社; 2019.
 
2) 原 悠, 金子 猛. 鎮咳薬・喀痰調節薬の使い分け. In: 片岡仁美, 編. レジデントノート増刊 Vol.21-No.5. 東京: 羊土社; 2019.p.72-6.
 
3) Paul IM, Shaffer ML, Yoder KE, et al. Dose-response relationship with increasing doses of dextromethorphan for children with cough. Clin Ther. 2004; 26: 1508-14.
PubMed
4) Pavesi L, Subburaj S, Porter-Shaw K. Application and validation of a computerizedcough acquisition system for objective monitoring of acute cough: a meta-analysis. Chest. 2001; 120: 1121-8.
PubMed
5) Catania MA, Cuzzocrea S. Pharmacological and clinical overview of cloperastine in treatment of cough. Ther Clin Risk Manag. 2011; 7: 83-92.
PubMed
6) Mohapatra PR, Aggarwal D. Carbocisteine for acute exacerbations of COPD. Lancet. 2008; 372: 1630-1; author reply 1631-2.
 
7) Malerba M, Ponticiello A, Radaeli A, et al. Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study(the AMETHIST Trial). Pulm Pharmacol Ther. 2004; 17: 27-34.
 
8) 日本アレルギー学会 喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 喘息予防・管理ガイドライン2021.東京: 協和企画; 2021.
 
9) Zheng JP, Wen FQ, Bai CX, et al. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease(PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014; 2: 187-94.
 
10) 福地義之助, 相澤久道, 一ノ瀬正和, 他. COPDの増悪に対するカルボシステインの臨床効果(PEACE STUDY). 呼吸. 2007; 26: 955-63.
Medical*Online
11) Zheng JP, Kang J, Huang SG, et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease(PEACE Study): a randomised placebo-controlled study. Lancet. 2008; 371: 2013-8.
PubMed
12) Richards D, Gever JR, Ford AP, et al. Action of MK-7264(gefapixant)at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitization. Br J Pharmacol. 2019; 176: 2279-91.
PubMed
13) McGarvey L, Birring S, Morice A, et al. Late breaking abstract -two phase 3 randomized clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough(COUGH-1 and COUGH-2). Eur Respir J. 2020; 56: 3800.
 
P.114 掲載の参考文献
1) 工藤翔二, 植竹健司, 萩原弘一, 他. びまん性汎細気管支炎にたいするエリスロマシン少量長期投与の臨床効果に関する研究 4年間の治療成績. 日胸疾患誌. 1987; 25: 632-42.
 
2) Omura S, Tsuzuki K, Sunazuka T et al. Gastrointestinal motor-stimulating activity of macrolide antibiotics and the structure-activity relationship. J Antibiot. 1985; 38: 1631-2.
PubMed
3) Tateda K, Standifold TJ, Pechere JC, et al. Regulatory effects of macrolides on bacterial virulence: potential role as quorum-sensing inhibitors. Curr Pharm Des. 2004; 10: 3022-65.
 
4) Tamaoki J. The effects of macrolides on inflammatory cells. Chest. 2004; 125: 41S-50S; quiz 51S.
 
5) Tamaoki J, Isono K, Sakai N, et al. Erythromycin inhibits Cl secretion across canine tracheal epithelial cells. Eur Respir J. 1992; 5: 234-8.
PubMed
6) Takeyama K, Tamaoki J, Chiyotani A, et al. Effect of macrolide antibiotics on ciliary motility in rabbit airway epithelium in vitro. J Pharm Pharmacol. 1993; 45: 756-8.
PubMed
7) Tagaya E, Tamaoki J, Kondo M, et al. Effect of a short course clarithromycin therapy on sputum production in patients with chronic airway hypersecretion. Chest. 2002; 122: 213-8.
 
8) Wong EH, Porter JD, Edward MR, et al. The role of macrolides in asthma: current evidence and future direction. Lancet Respir Med. 2014; 2: 657-70.
 
9) Simpson JL, Powell H, Boyle MJ, et al. Clarithromycin targets neutrophilic airway inflammation in refractory asthma. Am J Respir Crit Care Med. 2007; 177: 148-55.
PubMed
10) Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma(AZISAST): a multicentre randomised double-blind placebo-controlled trial. Thorax. 2013; 68: 322-9.
PubMed
11) Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma(AMAZES): A randomized , double-blind, placebo-controlled trial. Lancet. 2017; 390: 659-68.
PubMed
12) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 喘息予防・管理ガイドライン2021, 東京: 協和企画, 2021.
 
13) Global Strategy for Asthma Management and Prevention 2021 update. Global Initiative for Asthma.
 
14) Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest. 2001; 120: 730-3.
PubMed
15) Yamaya M, Azuma A, Tanaka H, et al. Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in COPD in Japan: a retrospective multicenter analysis. J Am Geriatr Soc. 2008; 56: 1358-60.
PubMed
16) 日本呼吸器学会COPDガイドライン第3版作成委員会:COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン第3版. 東京: メディカルレビュー社; 2009.
 
17) Seemugal TA, Wilkinson TM, Hurst JR, et al. Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbation. Am J Respir Crit Care Med. 2008; 178: 1139-47.
 
18) Global Initative for Chronic Obstructive Lung Disease(GOLD). GOLD 2022 Global Strategy for the Diagnosis Management and Prevention of COPD 2022
 
P.127 掲載の参考文献
1) 3学会合同呼吸リハビリテーションに関するステートメントワーキンググループ, 他. 日本呼吸ケア・リハビリテーション学会, 日本呼吸理学療法学会, 日本呼吸器学会 呼吸リハビリテーションに関するステートメント. 日本呼吸ケア・リハビリテーション学会誌. 2018; 27: 95-114.
 
2) Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007; 131(5 Suppl): 4S-42S. 4
 
3) Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease(2022 Report). <https://goldcopd.org/#>
 
4) 杉本恵申, 編. 診療点数早見表【2020年4月版】. 東京: 医学通信社; 2020. p.589.
 
5) 日本呼吸ケア・リハビリテーション学会呼吸リハビリテーション委員会ワーキンググループ. 日本呼吸器学会呼吸管理学術部会, 日本リハビリテーション医学会呼吸リハビリテーションガイドライン策定委員会, 日本理学療法士協会呼吸理学療法診療ガイドライン作成委員会. 呼吸リハビリテーションマニュアル -運動療法- 第2版. 東京: 照林社; 2012. p.2-8.
 
6) GOLD2011 日本語版監修 GOLD日本委員会, 福地義之助, 他. Global Initiative for Chronic Obstructive Lung Disease 日本語版 慢性閉塞性肺疾患の診断, 治療, 予防に関するグローバルストラテジー2011年 改訂版.<https://goldcopd.org/wp-content/uploads/2016/04/GOLDReport2011_Japanese.pdf>
 
7) 宮川哲夫. 呼吸リハビリテーションのEBM. MB Medical Rehabilitation. 2015; 189:1-13.
Medical*Online
8) 千住秀明, 他. 慢性閉塞性肺疾患(COPD)理学療法診療ガイドライン. <https://www.japanpt.or.jp/upload/jspt/obj/files/guideline/18_COPD_1.pdf>
Medical*Online
9) Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/EuropeanRespiratory Society statement: key concepts and advances in pulmonaryrehabilitation. Am J Respir Crit Are Med. 2013; 188: e13-64.
 
10) 神津 玲, 花田匡利, 千住秀明. びまん性肺疾患に対する呼吸リハビリテーション. 綜合臨牀. 2011; 60: 2455-62.
Medical*Online
11) 西山 理, 東田有智. 特発性間質性肺炎の非薬物治療. Respiratory Medical Research. 2914; 2: 118-24.
 
12) 渡邉文子, 近藤康博. 非COPD疾患のリハビリテーション. J Clin Rehabili. 2015;24: 463-8.
 
13) 「喘息予防・管理ガイドライン2018」作成委員. 喘息予防・管理ガイドライン2018. 東京: 協和企画; 2018. p.181-2.
 
14) 千田一嘉. COPDとサルコペニア. In: 近藤和泉, 編. 高齢者のフレイル(虚弱)とリハビリテーション. Medical Rehabilitation No170. 東京: 全日本病院出版会; 2014. p.69-75.
 
15) 日本静脈経腸栄養学会ガイドライン作成委員会. 慢性呼吸不全. 13. 日本静脈経腸栄養学会, 編. 静脈経腸栄養ガイドライン第3版. 東京: 照林社; 2014. p.274-81.
 
16) 慶應義塾大学スポーツ医学研究センター・大学院健康マネジメント研究科, 日本運動疫学会. 身体活動に関する世界行動計画 2018-2030. 健康的な世界に向けて一人一人よりアクティブに. 2020. <WHO GAPPA Japanese revise final2.pdf(keio.ac.jp)>
 
17) 小熊祐子. Global Action Plan on Physical Activity 2018-2030 について -SDGs, オリンピック・レガシーとともに考える-. 日本健康教育学会誌. 2020; 28: 92-100
 
P.137 掲載の参考文献
1) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 日本アレルギー学会喘息ガイドライン専門部会, 編. 喘息予防・管理ガイド ライン 2021.東京: 協和企画; 2021.
 
2) 日本喘息学会. 喘息診療実践ガイドライン2022.東京: 協和企画; 2022.
 
3) Dalal AA, Duh MS, Gozalo L, et al. Dose-response relationship between long-term systemic corticosteroid use and related complications in patients with severe asthma. J Manag Care Spec Pharm. 2016; 22: 833-47.
PubMed
4) Harada N, Ito J, Takahashi K. Clinical effects and immune modulation of biologics in asthma. Respir Investig. 2021; 59: 389-96.
PubMed
5) Galli SJ, Tsai M. IgE and mast cells in allergic disease. Nat Med. 2012; 18: 693-704.
PubMed
6) Ishizaka K, Ishizaka T. Identification of IgE. J Allergy Clin Immunol. 2016; 137: 1646-50.
 
7) Humbert M, Busse W, Hanania NA, et al. Omalizumab in asthma: an update on recent developments. J Allergy Clin Immunol Pract. 2014; 2: 525-36 e1.
 
8) McGregor MC, Krings JG, Nair P, et al. Role of Biologics in Asthma. Am J Respir Crit Care Med. 2019; 199: 433-45.
PubMed
9) Okayama Y, Matsumoto H, Odajima H, et al. Roles of omalizumab in various allergic diseases. Allergol Int. 2020; 69: 167-77.
PubMed
10) Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy(GINA 2002 step 4 treatment): INNOVATE. Allergy. 2005; 60: 309-16.
 
11) Ledford D, Busse W, Trzaskoma B, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017; 140: 162-9 e2.
 
12) Busse W, Corren J, Lanier BQ, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001; 108: 184-90.
PubMed
13) Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab(anti-IgE)for asthma in inner-city children. N Engl J Med. 2011; 364: 1005-15.
PubMed
14) Holgate ST, Chuchalin AG, Hebert J, et al. Efficacy and safety of a recombinant anti-immunoglobulin E antibody(omalizumab)in severe allergic asthma. Clin Exp Allergy. 2004; 34: 632-8.
PubMed
15) Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014: CD003559.
PubMed
16) Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001; 18: 254-61.
PubMed
17) Schroeder JT, Bieneman AP, Chichester KL, et al. Decreases in human dendritic cell-dependent T(H)2-like responses after acute in vivo IgE neutralization. J Allergy Clin Immunol. 2010; 125: 896-901 e6.
 
18) Djukanovic R, Wilson SJ, Kraft M, et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med. 2004; 170: 583-93.
PubMed
19) Amat F, Tallon P, Foray AP, et al. Control of asthma by omalizumab: the role of CD4( + ) Foxp3( + )regulatory T cells. Clin Exp Allergy. 2016; 46: 1614-6.
PubMed
20) Chand HS, Schuyler M, Joste N, et al. Anti-IgE therapy results in decreased myeloid dendritic cells in asthmatic airways. J Allergy Clin Immunol. 2010; 125: 1157-8 e5.
 
21) Romano C, Sellitto A, De Fanis U, et al. Omalizumab for difficult-to-treat dermatological conditions: clinical and immunological features from a retrospective real-life experience. Clin Drug Investig. 2015; 35: 159-68.
PubMed
22) Noga O, Hanf G, Brachmann I, et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol. 2006; 117: 1493-9.
 
23) Takaku Y, Soma T, Nishihara F, et al. Omalizumab attenuates airway inflammation and interleukin-5 production by mononuclear cells in patients with severe allergic asthma. Int Arch Allergy Immunol. 2013; 161 Suppl 2: 107-17.
 
24) Pelaia G, Gallelli L, Renda T, et al. Update on optimal use of omalizumab in management of asthma. J Asthma Allergy. 2011; 4: 49-59.
PubMed
25) Akdis CA, Arkwright PD, Bruggen MC, et al. Type 2 immunity in the skin and lungs. Allergy. 2020; 75: 1582-605.
PubMed
26) Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014; 371: 1198-207.
PubMed
27) Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma(DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012; 380: 651-9.
 
28) Bel EH, Wenzel SE, Thompson PJ, et al. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014; 371: 1189-97.
PubMed
29) Haldar P, Brightling CE, Hargadon B, et al. Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med. 2009; 360: 973-84.
PubMed
30) Nair P, Pizzichini MM, Kjarsgaard M, et al. Mepolizumab for prednisone-dependent asthma with sputum eosinophilia. N Engl J Med. 2009; 360: 985-93.
PubMed
31) Wright AKA, Diver S, McCarthy J, et al. Mepolizumab does not alter the blood basophil count in severe asthma. Allergy. 2019; 74: 2488-90.
 
32) Kelly EA, Esnault S, Liu LY, et al. Mepolizumab Attenuates Airway Eosinophil Numbers, but Not Their Functional Phenotype, in Asthma. Am J Respir Crit Care Med. 2017; 196: 1385-95.
PubMed
33) Sabogal Pineros YS, Bal SM, van de Pol MA, et al. Anti-IL-5 in mild asthma alters rhinovirus-induced macrophage, B-cell, and neutrophil responses(MATERIAL). A placebo-controlled, double-blind study. Am J Respir Crit Care Med. 2019; 199: 508-17.
PubMed
34) Buttner C, Lun A, Splettstoesser T, et al. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions. Eur Respir J. 2003; 21: 799-803.
 
35) Stein ML, Villanueva JM, Buckmeier BK, et al. Anti-IL-5(mepolizumab)therapy reduces eosinophil activation ex vivo and increases IL-5 and IL-5 receptor levels. J Allergy Clin Immunol. 2008; 121: 1473-83, 83 e1-4.
 
36) Kalinauskaite-Zukauske V, Januskevicius A, Janulaityte I, et al. Serum levels of epithelial-derived cytokines as interleukin-25 and thymic stromal lymphopoietin after a single dose of mepolizumab in patients with severe non-allergic eosinophilic asthma: a short report. Can Respir J. 2019; 2019: 8607657.
 
37) Mukherjee M, Forero DF, Tran S, et al. Sub-optimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena. Eur Respir J. 2020; 56: 2000117.
 
38) Andreev D, Liu M, Kachler K, et al. Regulatory eosinophils induce the resolution of experimental arthritis and appear in remission state of human rheumatoid arthritis. Ann Rheum Dis. 2021; 80: 451-68.
PubMed
39) Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists(SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016; 388: 2115-27.
 
40) Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017; 376: 2448-58.
PubMed
41) FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma(CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016; 388: 2128-41.
PubMed
42) Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021; 159: 496-506.
PubMed
43) Poznanski SM, Mukherjee M, Zhao N, et al. Asthma exacerbations on benralizumab are largely non-eosinophilic. Allergy. 2021; 76: 375-9.
PubMed
44) Pham TH, Damera G, Newbold P, et al. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016; 111: 21-9.
PubMed
45) Sridhar S, Liu H, Pham TH, et al. Modulation of blood inflammatory markers by benralizumab in patients with eosinophilic airway diseases. Respir Res. 2019; 20: 14.
PubMed
46) Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting beta2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016; 388: 31-44.
 
47) Castro M, Corren J, Pavord ID, et al. Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. N Engl J Med. 2018; 378: 2486-96.
PubMed
48) Rabe KF, Nair P, Brusselle G, et al. Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma. N Engl J Med. 2018; 378: 2475-85.
PubMed
49) Huang J, Pansare M. New treatments for asthma. Pediatr Clin North Am. 2019; 66: 925-39.
PubMed
50) Zayed Y, Kheiri B, Banifadel M, et al. Dupilumab safety and efficacy in uncontrolled asthma: a systematic review and meta-analysis of randomized clinical trials. J Asthma. 2019; 56: 1110-9.
 
51) Trichot C, Faucheux L, Karpf L, et al. TH cell diversity and response to dupilumab in patients with atopic dermatitis. J Allergy Clin Immunol. 2021; 147: 756-9.
PubMed
52) Patel G, Pan J, Ye L, et al. Blockade of IL-4Ralpha inhibits group 2 innate lymphoid cell responses in asthma patients. Clin Exp Allergy. 2020; 50: 267-70.
 
53) Corren J, Parnes JR, Wang L, et al. Tezepelumab in adults with uncontrolled asthma. N Engl J Med. 2017; 377(10): 936-46.
PubMed
54) Diver S, Khalfaoui L, Emson C, et al. Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma(CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2021; 9: 1299-312.
PubMed
55) Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma. N Engl J Med. 2021; 384: 1800-9.
PubMed
56) Wechsler ME, Colice G, Griffiths JM, et al. SOURCE: a phase 3, multicentre, randomized, double-blind, placebo-controlled, parallel group trial to evaluate the efficacy and safety of tezepelumab in reducing oral corticosteroid use in adults with oral corticosteroid dependent asthma. Respir Res. 2020; 21: 264.
PubMed
57) Wechsler ME, Menzies-Gow A, Brightling CE, et al. Evaluation of the oral corticosteroid-sparing effect of tezepelumab in adults with oral corticosteroid-dependent asthma(SOURCE): a randomised, placebo-controlled, phase 3 study. Lancet Respir Med. 2022; 10: 650-60.
PubMed
58) Castro M, Rubin AS, Laviolette M, et al. Effectiveness and safety of bronchial thermoplasty in the treatment of severe asthma: a multicenter, randomized, double-blind, sham-controlled clinical trial. Am J Respir Crit Care Med. 2010; 181: 116-24.
PubMed
59) Trivedi A, Pavord ID, Castro M. Bronchial thermoplasty and biological therapy as targeted treatments for severe uncontrolled asthma. Lancet Respir Med. 2016; 4: 585-92.
PubMed
60) Wechsler ME, Laviolette M, Rubin AS, et al. Bronchial thermoplasty: Long-term safety and effectiveness in patients with severe persistent asthma. J Allergy Clin Immunol. 2013; 132: 1295-302
 
P.148 掲載の参考文献
1) Haahtela T, Jarvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med. 1994; 331: 700-5.
 
2) Takaku Y, Nakagome K, Kobayashi T, et al. Changes in airway inflammation and hyperresponsiveness after inhaled corticosteroid cessation in allergic asthma. Int Arch Allergy Immunol. 2010; 152 Suppl 1: 41-6.
 
3) Nagata M, Nakagome K. Allergen immunotherapy in asthma: current status and future perspectives. Allergol Int. 2010; 59: 15-9.
PubMed
4) Nakagome K, Nagata M. Role of allergen immunotherapy in asthma treatment and asthma development. Allergies. 2021; 1: 33-45.
 
5) 日本アレルギー学会「アレルゲン免疫療法の手引き」作成委員会. アレルゲン免疫療法 の手引き. 東京: 協和企画; 2022.
 
6) Abramson MJ, Puy RM, Weiner JM. Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995; 151: 969-74.
PubMed
7) Dhami S, Kakourou A, Asamoah F, et al. Allergen immunotherapy for allergic asthma: A systematic review and meta-analysis. Allergy. 2017; 72: 1825-48.
PubMed
8) Maestrelli P, Zanolla L, Pozzan M, et al. Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol. 2004; 113: 643-9.
PubMed
9) Uchida T, Nakagome K, Iemura H, et al. Clinical evaluation of rush immunotherapy using house-dust mite allergen in Japanese asthmatics. Asia Pac Allergy. 2021; 11: e32.
PubMed
10) U. S. Department of Health and Human Services: National Heart, Lung, and Blood Institute. National Asthma Education and Prevention Program. Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma. 2007.
 
11) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 喘息予防・管理ガイドライン2021.東京: 協和企画; 2021.
 
12) Ohta K, Bousquet PJ, Aizawa H, et al. Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. Allergy. 2011; 66: 1287-95.
 
13) Corren J, Adinoff AD, Irvin CG. Changes in bronchial responsiveness following nasal provocation with allergen. J Allergy Clin Immunol. 1992; 89: 611-8.
PubMed
14) Braunstahl GJ, Kleinjan A, Overbeek SE, et al. Segmental bronchial provocation induces nasal inflammation in allergic rhinitis patients. Am J Respir Crit Care Med. 2000; 161: 2051-7.
PubMed
15) Bousquet J, Khaltaev N, Cruz AA, et al. Allergic rhinitis and its impact on asthma(ARIA)2008 update(in collaboration with the World Health Organization, GA2LEN and AllerGen). Allergy. 2008; 63 Suppl 86: 8-160.
 
16) Crystal-Peters J, Neslusan C, Crown WH, et al. Treating allergic rhinitis in patients with comorbid asthma: the risk of asthma-related hospitalizations and emergency department visits. J Allergy Clin Immunol. 2002; 109: 57-62.
PubMed
17) 仲田拡人, 中込一之, 高久洋太郎, 他. 鼻炎症状と喘息症状の連関についてのアンケー ト調査. アレルギー. 2010; 59: 688-98.
Medical*Online
18) Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med. 1999; 341: 468-75.
PubMed
19) Jacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007; 62: 943-8.
PubMed
20) Marogna M, Spadolini I, Massolo A, et al. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010; 126: 969-75
 
21) Moller C, Dreborg S, Ferdousi HA, et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol. 2002; 109: 251-6.
PubMed
22) 永田 真, 田部一秋, 山本英明, 他. ダニ抗原過敏性成人気管支喘息における抗原特異的免疫療法の臨床的意義. アレルギー. 1999; 48: 1316-21.
 
23) Mosbech H, Deckelmann R, de Blay F, et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet(ALK)reduces inhaled corticosteroid use while maintaining asth00ma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol. 2014; 134: 568-75.
 
24) Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA. 2016; 315: 1715-25.
PubMed
25) Global Initiative for Asthma. Global strategy for the diagnosis and prevention. Global Initiative for Asthma(updated 2020).
 
26) Hoshino M, Akitsu K, Kubota K. Effect of sublingual immunotherapy on airway inflammation and airway wall thickness in allergic asthma. J Allergy Clin Immunol Pract. 2019; 7: 2804-11.
PubMed
27) Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and safety of HDM SLIT tablet in Japanese adults with allergic Asthma. J Allergy Clin Immunol Pract. 2020; 8: 710-20.
PubMed
28) Marogna M, Spadolini I, Massolo A, et al. Long-term comparison of sublingual immunotherapy vs inhaled budesonide in patients with mild persistent asthma due to grass pollen. Ann Allergy Asthma Immunol. 2009; 102: 69-75.
PubMed
29) Kikkawa S, Nakagome K, Kobayashi T, et al. Sublingual immunotherapy for Japanese cedar pollinosis attenuates asthma exacerbation. Allergy Asthma Immunol Res. 2019; 11: 438-40.
PubMed
30) Di Bona D, Plaia A, Leto-Barone MS, et al. Efficacy of allergen immunotherapy in reducing the likelihood of developing new allergen sensitizations: a systematic review. Allergy. 2017; 72: 691-704.
PubMed
31) Inal A, Altintas DU, Yilmaz M, et al. Prevention of new sensitizations by specific immunotherapy in children with rhinitis and/or asthma monosensitized to house dust mite. J Investig Allergol Clin Immunol. 2007; 17: 85-91.
PubMed
32) Gulen F, Zeyrek D, Can D, et al. Development of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. Asian Pac J Allergy Immunol. 2007; 25: 7-11
 
P.155 掲載の参考文献
1) 日本呼吸器学会 COPD ガイドライン第5版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン.第5版. 東京: メディカルレビュー社; 2018.
 
2) e-STAT. 人口動態調査-人口動態統計 確定数 死亡. 下巻 死亡数, 死因(死因簡単分類)・性・年齢(5歳階級)別.https://www.e-stat.go.jp/stat-search/files?page=1&layout=datalist&toukei=00450011&tstat=000001028897&cycle=7&year=20200&month=0&tclass1=000001053058&tclass2=000001053061&tclass3=000001053065&result_back=1&tclass4val=0>
 
3) Sharma G, Goodwin J. Effect of aging on respiratory system physiology andimmunology. Clin Interv Aging. 2006; 1: 253-60.
 
4) 岩永賢司, 東田有智. 高齢者喘息への対応. Respiratory Medical Research. 2015; 3: 249-53.
Medical*Online
5) 岩永賢司, 東田有智. 気管支喘息: 診断と治療の進歩 3.高齢者喘息. 日内会誌. 2013; 102: 1343-51.
 
6) Gibson PG, McDonald VM, Marks GB. Asthma in older adults. Lancet. 2010; 676: 803-13.
 
7) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 喘息予防・管理ガイドライン 2021.東京: 協和企画; 2021.
 
8) Molimard M , Raherison C, Lignot S, et al. Assessment of handling of inhaler devicesin real life: An observational study in 3811 patients in primary care. J Aerosol Med. 2003: 16: 249-54.
 
9) 東田有智, 岩永賢司, 佐野博幸. 高齢者喘息の病態解明と治療・管理法の確立に関する研究. 厚生労働科学研究費補助金(免疫アレルギー疾患予防・治療研究事業)分担研究年度終了報告書. 2017.
 
10) Barr RG. Patient's factors and medication guideline adherence among older women with asthma. Arch Intern Med. 2002; 162: 1761-8.
 
11) Buist AS, Vollmer WM, Wilson SR, et al. A randomized clinical trial of peak flow versus symptom monitoring in older adults with asthma. Am J Respir Crit Care Med. 2006: 174: 1077-87.
PubMed

III 各種気道疾患と診療のポイント

P.166 掲載の参考文献
1) Tormanen S, Lauhkonen E, Riikonen R, et al. Risk factors for asthma after infantbronchiolitis Allergy. 2018; 73: 916-22.
PubMed
2) Jackson DJ, Gangnon RE, Evans MD, et al. Wheezing rhinovirus illnesses in early life predict asthma development in high-risk children. Am J Respir Crit Care Med. 2008; 178: 667-72.
 
3) Chung KF. Airway microbial dysbiosis in asthmatic patients: A target for prevention and treatment? J Allergy Clin Immunol. 2017; 139: 1071-81.
PubMed
4) Edwards KM, Zhu Y, Griffin MR, et al. Burden of human metapneumovirus infection in young children. N Engl J Med. 2013; 368: 633-43.
PubMed
5) Pizzichini MM, Pizzichini E, Efthimiadis A, et al. Asthma and natural colds. Inflammatory indices in induced sputum: a feasibility study. Am J Respir Crit Care Med. 1998; 158: 1178-84.
PubMed
6) Busse WW, Morgan WJ, Gergen PJ, et al. Randomized trial of omalizumab(anti-IgE)for asthma in inner-city children. N Engl J Med. 2011; 364: 1005-15.
PubMed
7) Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med. 2011; 184: 662-71.
PubMed
8) Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA. 2013; 309: 2223-31.
PubMed
9) Sivapalan P, Ingebrigtsen TS, Rasmussen DB, et al. COPD exacerbations: the impact of long versus short courses of oral corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months. BMJ Open Respir Res. 2019; 6: e000407.
PubMed
10) Westerdahl E, Osadnik C, Emtner M. Airway clearance techniques for patients with acute exacerbations of chronic obstructive pulmonary disease: Physical therapy practice in Sweden. Chron Respir Dis. 2019; 16: 1479973119855868.
PubMed
11) Lee MK, Choi J, Park B, et al. High flow nasal cannulae oxygen therapy in acute-moderate hypercapnic respiratory failure. Clin Respir J. 2018: 2046-56.
PubMed
12) Furumoto A, Ohkusa Y, Chen M, et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine. 2008; 26: 4284-9.
PubMed
13) Berghaus TM, Karschnia P, Haberl S, et al. Disproportionate decline in admissions for exacerbated COPD during the COVID-19 pandemic. Respir Med. 2022; 191: 106120.
PubMed
14) Stein RT, Sherrill D, Morgan WJ, et al. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet. 1999; 354: 541-5.
PubMed
15) Yamada Y, Matsumoto K, Hashimoto N, et al. Effect of Th1/Th2 cytokine pretreatment on RSV-induced gene expression in airway epithelial cells. Int Arch Allergy Immunol. 2011; 154: 185-94.
PubMed
16) Bacharier LB, Cohen R, Schweiger TY, et al. Determinants of asthma after severe respiratory syncytial virus bronchiolitis. J Allergy Clin Immunol. 2012; 130: 91-100. e3.
 
17) Fukushima C, Matsuse H, Fukahori S, et al. Aspergillus fumigatus synergistically enhances mite-induced allergic airway inflammation. Med Sci Monit. 2010; 16: BR197-202.
PubMed
P.180 掲載の参考文献
1) 新実彰男. 咳嗽診療の心得「たかが咳, されど咳」. 日内会誌. 2020; 109: 2091-4.
 
2) Niimi A, Kihara Y, Sumita Y, et al. Cough reflex by premature ventricular contractions. Int Heart J. 2005; 46: 923-6.
PubMed
3) Niimi A. Natural language processing: A promising research tool of chronic cough for the big data era. Chest. 2021; 159: 2149-50.
PubMed
4) 日本呼吸器学会. 咳嗽・喀痰の診療ガイドライン2019.東京: メディカルレビュー社; 2019.
 
5) Mukae H, Kaneko T, Obase Y, et al. The Japanese respiratory society guidelines for the management of cough and sputum(digest edition). Respir Investig. 2021; 59: 270-90.
 
6) 日本咳嗽学会. 専門医のための遷延性・慢性咳嗽の診断と治療に関する指針2021年度版. 金沢: 前田書店; 2021.
 
7) 新実彰男. 慢性咳嗽の病態, 鑑別診断と治療-咳喘息を中心に-. 日内会誌. 2016; 105: 1565-77.
 
8) Kanemitsu Y, Kurokawa R, Takeda N, et al. Clinical impact of gastroesophageal reflux disease in patients with subacute/chronic cough. Allergol Int. 2019; 68: 478-85.
PubMed
9) 新実彰男. 電子コンテンツ「長引く咳の診かた」. 東京: 日本医事新報社; 2019.<https://www.jmedj.co.jp/premium/pcou/(購入者限定コンテンツ)>
 
10) Jinnai M, Niimi A, Ueda T, et al. Induced sputum concentrations of mucin in patients with asthma and chronic cough. Chest. 2010; 137: 1122-9.
PubMed
11) Niimi A, Ohbayashi H, Sagara H, et al. Cough variant and cough-predominant asthma are major causes of persistent cough: a multicenter study in Japan. J Asthma. 2013; 50: 932-7.
PubMed
12) Niimi A. Cough associated with gastro-oesophageal reflux disease: Japanese experience. Pulm Pharmacol Ther. 2017; 47: 59-65.
PubMed
13) Niimi A. Geography and cough aetiology. Pulm Pharmacol Ther. 2007; 20: 383-7.
PubMed
14) Tajiri T, Kawachi H, Yoshida H, et al. The causes of acute cough: a tertiary-care hospital study in Japan. J Asthma. 2021; 58: 1495-501.
PubMed
15) Ford AC, Forman D, Moayyedi P, et al. Cough in the community: a cross sectional survey and the relationship to gastrointestinal symptoms. Thorax. 2006; 61: 9759.
 
16) Fujimura M. Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey. Allergol Int. 2012; 61: 573-81.
PubMed
17) Matsumoto H, Izuhara Y, Niimi A, et al. Nagahama Study Collaboration Group. Risks and cough-aggravating factors in prolonged cough. Epidemiological observations from the Nagahama Cohort Study. Ann Am Thorac Soc. 2017; 14: 698-705.
PubMed
18) Satia I, Tsamandouras N, Holt K, et al. Capsaicin-evoked cough responses in asthmatic patients: Evidence for airway neuronal dysfunction. J Allergy Clin Immunol. 2017; 139: 771-9.e10.
 
19) Fukumitsu K, Kanemitsu Y, Asano T, et al. Tiotropium attenuates refractory cough and capsaicin cough reflex sensitivity in patients with asthma, J Allergy Clin Immunol Pract. 2018; 6: 1613-20.
PubMed
20) Mazzone SB, McGarvey L. Mechanisms and rationale for targeted therapies in refractory and unexplained chronic cough. Clin Pharmacol Ther. 2021; 109: 619-36.
PubMed
21) Dicpinigaitis PV, Enilari O, Cleven KL. Prevalence of Arnold nerve reflex in subjects with and without chronic cough: relevance to cough hypersensitivity syndrome. Pulm Pharmacol Ther. 2019; 54: 22-4.
PubMed
22) Kanemitsu Y, Matsumoto H, Oguma T, et al. Independent factors contributing to daytime and nighttime asthmatic cough refractory to inhaled corticosteroids. J Investig Allergol Clin Immunol. 2019; 29: 30-9.
PubMed
23) Niimi A. How long should patients with cough variant asthma or non-asthmatic eosinophilic bronchitis be treated? J Thorac Dis. 2021; 13: 3197-214.
PubMed
24) Tajiri T, Niimi A, Matsumoto H, et al. Prevalence and clinical relevance of allergic rhinitis in patients with classic asthma and cough variant asthma. Respiration. 2014; 87: 211-8.
PubMed
25) Niimi A, Fukumitsu K, Takeda N, et al. Interfering with airway nerves in cough associated with asthma. Pulm Pharmacol Ther. 2019; 59: 101854.
PubMed
26) Watanabe H, Shirai T, Akamatsu T, et al. Forced oscillatory parameters in reversibility testing as predictors for chronic cough responsive to inhaled corticosteroid/long-acting b2 agonist. Ann Allergy Asthma Immunol. 2019; 122: 335-6.
 
27) Asano T, Takemura M, Kanemitsu Y, et al. Diagnostic utility of fractional exhaled nitric oxide in prolonged and chronic cough according to atopic status. Allergol Int. 2017; 66: 344-50.
PubMed
28) Takemura M, Niimi A, Matsumoto H, et al. Clinical, physiological and anti-inflammatory effect of montelukast in patients with cough variant asthma. Respiration. 2012; 83: 308-15.
PubMed
29) Kanemitsu Y, Takakuwa O, Fukumitsu K, et al. Bronchial thermoplasty for severe asthmatic cough. Ann Intern Med. 2018; 169: 61-2.
PubMed
30) Matsuoka H, Niimi A, Matsumoto H, et al. Inflammatory subtypes in cough-variant asthma: association with maintenance doses of inhaled corticosteroids. Chest. 2010; 138: 1418-25.
PubMed
31) Morales DR, Lipworth BJ, Donnan PT, et al. Intolerance to angiotensin converting enzyme inhibitors in asthma and the general population: a UK population-based cohort study. J Allergy Clin Immunol Pract. 2021; 9: 3431-9.e4.
 
32) Song WJ, Niimi A. Angiotensin converting enzyme inhibitors, asthma, and cough: relighting the torch. J Allergy Clin Immunol Pract. 2021; 9: 3440-1.
PubMed
33) Takeda N, Takemura M, Kanemitsu Y, et al. Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation. J Asthma. 2020; 57: 1202-10.
PubMed
34) Kurokawa R, Kanemitsu Y, Fukumitsu K, et al. The diagnostic utility of the frequency scale for the symptoms of gastroesophageal reflux disease questionnaire(FSSG)for patients with subacute/chronic cough. J Asthma. 2021; 58: 1502-11.
 
35) Kurokawa R, Kanemitsu Y, Fukumitsu K, et al. Reflux-related symptoms reflect poor asthma control and the presence of airway neuronal dysfunction. Allergol Int. 2022; 71: 318-24.
PubMed
36) Kanemitsu Y, Niimi A, Matsumoto H, et al. Gastroesophageal dysmotility is associated with the impairment of cough-specific quality of life in patients with cough variant asthma. Allergol Int. 2016; 65: 320-6.
PubMed
37) Kanemitsu Y, Fukumitsu K, Kurokawa R, et al. Increased capsaicin sensitivity in severe asthmatics associated with worse clinical outcome. Am J Respir Crit Care Med. 2020; 201: 1068-77.
PubMed
38) Niimi A. Redefining"one airway, one disease": Broader classification considering specific pathophysiology and treatment. Respir Invest. 2021; 59: 573-5.
 
39) Wang K, Birring SS, Taylor K, et al. Montelukast for postinfectious cough in adults: a double-blind randomised placebo-controlled trial. Lancet Respir Med. 2014; 2: 35-43.
PubMed
40) Niimi A, Chung KF. Evidence for neuropathic processes in chronic cough. Pulm Pharmacol Ther. 2015; 35: 1004.
 
41) 新実彰男. 難治性慢性咳嗽の病態と新たな治療展開. アレルギー. 2021; 70: 112-7.
Medical*Online
42) McGarvey LP, Birring SS, Morice AH, et al. COUGH-1 and COUGH-2 Investigators. Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet. 2022; 399: 909-23.
PubMed
43) Niimi A, Sagara H, Kikuchi M, et al. A phase 3, randomized, double-blind, clinical study to evaluate the long-term safety and efficacy of gefapixant in Japanese adult participants with refractory of unexplained chronic cough. Allergol Int. 2022; 71: 498-504.
 
44) 新実彰男. P2X3 受容体拮抗薬(アレルギー用語解説シリーズ). アレルギー. 2022; 71: 338-40.
 
45) Niimi A, Saito J, Kamei T, et al. Randomised trial of the P2X3 receptor antagonist sivopixant for refractory chronic cough. Eur Respir J. 2022: 59: 2100725
PubMed
P.196 掲載の参考文献
1) 日本アレルギー学会喘息ガイドライン専門部会「喘息予防・管理ガイドライン2021」作成委員会. 日本アレルギー学会喘息ガイドライン専門部会, 編. 喘息予防・管理ガイドライン2021.東京: 協和企画; 2021.
 
2) 日本喘息学会. 喘息診療実践ガイドライン2022.東京: 協和企画; 2022.
 
3) 日本アレルギー学会, 監修. 皮膚テストの手引き. 東京: 協和企画; 2021.
 
4) 日本呼吸器学会難治性喘息診断と治療の手引き2019作成委員会, 編. 難治性喘息診断と治療の手引き 2019.東京: メディカルレビュー社; 2019.
 
5) 日本呼吸器学会喘息とCOPDのオーバーラップ(Asthma and COPD Overlap: ACO)診断と治療の手引き2018作成委員会, 編. 喘息とCOPDのオーバーラップ(Asthma and COPD Overlap: ACO)診断と治療の手引き2018.東京: メディカルレビュー社; 2018.
 
6) 日本喘息学会HP. 吸入操作ビデオ.<https://jasweb.or.jp/movie.html>
 
7) 日本アレルギー学会. アレルギー総合診療のための分子標的治療の手引き. 東京: 協和企画. 2022.
 
P.207 掲載の参考文献
1) Sasaki M, Morikawa E, Yoshida K, et al. The change in the prevalence of wheeze, eczema and rhino-conjunctivitis among Japanese children: Findings from 3 nationwide cross-sectional surveys between 2005 and 2015.Allergy. 2019; 74: 1572-5.
PubMed
2) Arakawa H, Hamasaki Y, Kohno Y, et al. Japanese guidelines for childhood asthma 2017.Allergol Int. 2017; 66: 190-204.
PubMed
3) 日本小児アレルギー学会. 小児気管支喘息治療・管理ガイドライン2020. 東京: 協和企画; 2020.
 
4) Sunyer J, Anto JM, Kogevinas M, et al. Risk factors for asthma in young adults. Spanish Group of the European Community Respiratory Health Survey. Eur Respir J. 1997; 10: 2490-4.
PubMed
5) Wijga A, Tabak C, Postma DS, et al. Sex differences in asthma during the first 8 years of life: The Prevention and Incidence of Asthma and Mite Allergy(PIAMA)birth cohort study. J Allergy Clin Immunol. 2011; 127: 275-7.
PubMed
6) Tran MM, Lefebvre DL, Dharma C, et al. Predicting the atopic march: Results from the Canadian Healthy Infant Longitudinal Development Study. J Allergy Clin Immunol. 2018; 141: 601-7.
PubMed
7) Huang CC, Chiang TL, Chen PC, et al. Risk factors for asthma occurrence in children with early-onset atopic dermatitis: An 8-year follow-up study. Pediatr Allergy Immunol. 2018; 29: 159-65.
PubMed
8) Lowe AJ, Angelica B, Su J, et al. Age at onset and persistence of eczema are related to subsequent risk of asthma and hay fever from birth to 18 years of age. Pediatr Allergy Immunol. 2017; 28: 384-90.
PubMed
9) Illi S, von Mutius E, Lau S, et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet. 2006; 368: 763-70.
PubMed
10) Kusel MM, de Klerk NH, Kebadze T, et al. Early-life respiratory viral infections, atopic sensitization, and risk of subsequent development of persistent asthma. J Allergy Clin Immunol. 2007; 119: 1105-10.
PubMed
11) Abe K, Miyawaki A, Nakamura M, et al. Trends in hospitalizations for asthma during the COVID-19 outbreak in Japan. J Allergy Clin Immunol Pract. 2021; 9: 494-6.e1.
 
12) Lodge CJ, Braback L, Lowe AJ, et al. Grandmaternal smoking increases asthma risk in grandchildren: A nationwide Swedish cohort. Clin Exp Allergy. 2018; 48: 167-74.
PubMed
13) Stein MM, Hrusch CL, Gozdz J, et al. Innate Immunity and Asthma Risk in Amish and Hutterite Farm Children. N Engl J Med. 2016; 375: 411-21.
PubMed
14) Kikkawa T, Yorifuji T, Fujii Y, et al. Birth order and paediatric allergic disease: A nationwide longitudinal survey. Clin Exp Allergy. 2018; 48: 577-85.
PubMed
15) Yamamoto-Hanada K, Yang L, Narita M, et al. Influence of antibiotic use in early childhood on asthma and allergic diseases at age 5.Ann Allergy Asthma Immunol. 2017; 119: 54-8.
PubMed
16) Fujita S, Suzuki R, Sagara N, et al. Three cases of diffuse panbronchiolitis in children with a past history of difficult-to-treat bronchial asthma: A case report from a single medical facility. Allergol Int. 2020; 69: 468-70.
PubMed
17) Chang TS, Lemanske RF Jr, Guilbert TW, et al. Evaluation of the modified asthma predictive index in high-risk preschool children. J Allergy Clin Immunol Pract. 2013; 1: 152-6.
PubMed
18) Amin P, Levin L, Epstein T, et al. Optimum predictors of childhood asthma: persistent wheeze or the Asthma Predictive Index? J Allergy Clin Immunol Pract. 2014; 2: 709-15.
PubMed
P.220 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン第6版作成委員会, 編. COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン2022[第6版]. 東京: メディカルレビュー社; 2022.
 
2) 日本呼吸器学会. 新型コロナウイルス感染症流行期における呼吸機能検査の実施について. 日本呼吸器学会ホームページ.
 
3) 日本呼吸器学会閉塞性肺疾患学術部会. COVID-19流行期日常診療における慢性閉塞性肺疾患(COPD)の作業診断と管理手順. 日本呼吸器学会ホームページ.
 
4) Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011; 364: 1093-103.
PubMed
5) Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009; 34: 648-54.
PubMed
6) Global initiative for chronic obstructive pulmonary disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2022 report.
 
7) 厚生労働省, 新型コロナウイルス感染症(COVID-19) 診療の手引き・第6.2版. 厚生労働省ホームページ.
 
8) Samukawa T, Matsumoto K, Tsukuya G, et al. Development of a self-scored persistent airflow obstruction screening questionnaire in a general Japanese population: the Hisayama study. Int J Chron Obstruct Pulmon Dis. 2017; 12: 1469-81.
 
9) Martinez FJ, Raczek AE, Seifer FD, et al. Development and initial validation of a self-scored COPD Population Screener Questionnaire(COPD-PS). COPD. 2008; 5: 85-95.
PubMed
P.228 掲載の参考文献
1) Gibson PG, McDonald VM. Asthma-COPD overlap 2015: now we are six. Thorax. 2015; 70: 683-91.
PubMed
2) 日本呼吸器学会 喘息とCOPDのオーバーラップ(Asthma and COPD Overlap: ACO)診断と治療の手引き2018作成委員会, 編. 喘息とCOPDのオーバーラップ(Asthma and COPD Overlap: ACO)診断と治療の手引き2018.東京: メディカルレビュー社; 2017.
 
3) Silva GE, Sherrill DL, Guerra S, et al. Asthma as a risk factor for COPD in a longitudinal study. Chest. 2004; 126: 59-65.
 
P.238 掲載の参考文献
1) Hinson KF, Moon AJ, Plummer NS. Broncho-pulmonary aspergillosis: a review and a report of eight new cases. Thorax. 1952; 7: 317-33.
 
2) Ueki S, Hebisawa A, Kitani M, et al. Allergic bronchopulmonary aspergillosis-a luminal hypereosinophilic disease with extracellular trap cell death. Front Immunol. 2018; 9: 2346.
PubMed
3) Oguma T, Taniguchi M, Shimoda T, et al. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergol Int. 2018; 67: 79-84.
PubMed
4) 「アレルギー性気管支肺真菌症」研究班, 日本アレルギー学会, 日本呼吸器学会. アレルギー性気管支肺真菌症の診療の手引き. 1版. 東京: 医学書院; 2019.
 
5) Oguma T, Taniguchi M, Shimoda T, et al. Allergic bronchopulmonary aspergillosis in Japan: A nationwide survey. Allergol Int. 2018; 67: 79-84.
PubMed
6) Chowdhary A, Agarwal K, Kathuria S, et al. Allergic bronchopulmonary mycosis due to fungi other than Aspergillus: a global overview. Crit Rev Microbiol. 2014; 40: 30-48.
PubMed
7) Shah A, Kala J, Sahay S, et al. Frequency of familial occurrence in 164 patients with allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol. 2008; 101: 363-9.
PubMed
8) 蛇澤 晶, 田村厚久, 倉島篤行, 他. 手術例から見たアレルギー性気管支肺アスペルギルス症・真菌症の病理形態学的研究. 日呼吸会誌. 1998; 36: 330-7.
 
9) Sehgal IS, Agarwal R. Specific IgE is better than skin testing for detecting Aspergillus sensitization and allergic bronchopulmonary aspergilosis in asthma. Chest. 2015; 147: e194.
 
10) Baxter CG, Denning DW, Jones AM, et al. Performance of two Aspergillus IgG EIA assays compared with the precipitin test in chronic and allergic aspergillosis. Clin microbiol infect. 2013; 19: E197-204.
 
11) Agarwal R, Dua D, Choudhary H, et al. Role of Aspergillus fumigatus-specific IgG in diagnosis and monitoring treatment response in allergic bronchopulmonary aspergillosis. Mycoses. 2017; 60: 33-9.
PubMed
12) Harada K, Ogima T, Saito A, et al. Concordance between Aspergillus-specific precipitating antibody and IgG in allergic bronchopulmonary aspergillosis. Allergol int. 2018; 67S: S12-17.
 
13) Suzuki S, Asakura T, Namkoong H, et al. Aspergillus precipitating antibody in patients with Mycobacterium avium complex lung disease: A cross-sectional study. Respir Med. 2018; 138: 1-6.
PubMed
14) Asano K, Hebisawa A, Ishiguro T, et al. New clinical diagnostic criteria for allergic bronchopulmonary aspergillosis/mycosis and its validation. J Allergy Clin Immunol. 2021; 147: 1261-8.
PubMed
15) Patterson R, Greenberger PA, Radin RC, et al. Allergic bronchopulmonary aspergillosis: staging as an aid to management. Ann Intern Med. 1982; 96: 286-91.
PubMed
16) Agarwal R, Chakrabarti A, Shah A, et al. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013; 43: 850-73.
PubMed
17) Agarwal R, Aggarwal AN, Dhooria S, et al. A randomized trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2016; 47: 490-8.
PubMed
18) Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of itraconazole vs prednisolone in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Chest. 2018; 153: 656-6.
PubMed
19) Agarwal R, Dhooria S, Singh Sehgal I, et al. A randomized trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma. Eur Respir J. 2018; 52: 1801159.
 
20) Ishiguro T, Kagiyama N, Kojima A, et al. Allergic bronchopulmonary mycosis due to Schizophyllum commune treated effectively with voriconazole. Intern Med. 2018; 57: 2553-7.
PubMed
21) Li JX, Fan LC, Li MH, et al. Beneficial effects of omalizumab therapy in allergic bronchopulmonary aspergillosis: A synthesis review of published literature. Respir Med. 2017; 122: 33-42.
PubMed
22) Tolebeyan A, Mohammadi O, Vaezi Z, et al. Mepolizumab as possible treatment for allergic bronchopulmonary aspergillosis: A review of eight cases. Cureus. 2020; 12: e9684.
PubMed
23) Matsuura H, Fujiwara K, Omori H, et al. Successful treatment with benralizumab for allergic bronchopulmonary aspergillosis that developed after disastrous heavy rainfall in western Japan. Intern Med. 2021; 60: 1443-50.
PubMed
24) Ali M, Green O. Dupilumab: a new contestant to corticosteroid in allergic bronchopulmonary aspergillosis. Oxf Med Case Reports. 2021; omaa029.
PubMed
25) 宇留賀公紀, 今福 礼, 花田豪郎, 他. Hyperattenuating mucoid impaction を呈したスエヒロタケによるアレルギー性気管支肺真菌症の1例. 日呼吸会誌. 2010; 48: 749-54.
Medical*Online
26) WHO-IUIS Allergen Nomenclature database <http://www.allergen.org>
 
27) Tanimoto H, Fukutomi Y, Tasueda H, et al. Molecular-based allergy diagnosis of allergic bronchopulmonary aspergillosis in Aspergillus fumigatus-sensitized Japanese patients. Clin Exp Allergy. 2015; 45: 1790-800.
 
P.248 掲載の参考文献
1) Hill AT, Sullivan AL, Chalmers JD, et al. British Thoracic Society Guideline for bronchiectasis in adults. Thorax. 2019; 74: 1-69.
PubMed
2) Polverino E, Goeminne PC, McDonnell MJ, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017; 50: 170629.
 
3) Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An international derivation and validation study. Am J Respir Crit Care. 2014; 189: 576-85.
 
4) Finch S, Laska IF, Abo-Leyah H, et al. Validation of the COPD Assessment Test(CAT)as an outcome measure in bronchiectasis. Chest. 2020; 157: 815-23.
PubMed
5) Lee AL, Burge AT, Holland AE. Positive expiratory pressure therapy versus other airway clearance techniques for bronchiectasis. Cochrane Database Syst Rev. 2017; 9: CD011699.
PubMed
6) Coppolo DP, Schloss J, Suggett JA, et al. Non-pharmaceutical techniques for obstructive airway clearance focusing on the role of oscillating positive expiratory pressure(OPEP): a narrative review. Pulm Ther. 2022; 8: 1-41.
PubMed
7) Crichton ML, Shoemark A, Chalmers JD. The impact of the COVID-19 pandemic on exacerbations and symptoms in bronchiectasis: A prospective study. Am J Respir Crit Care Med. 2021; 204: 857-9.
PubMed
8) Chalmers JD. Haworth CS, Metersky ML, et al. Phase 2 trial of the DPP-1 inhibitor brensocatib in bronchiectasis. N Engl J Med. 2020; 383: 2127-37.
PubMed
9) Matsumoto H. Bronchiectasis in severe asthma and asthmatic components in bronchiectasis. Respir Invest. 2022; 60: 187-96.
 
10) Chalmers JD, Chang AB, Chotirmall SH, et al. Bronchiectasis. Nat Rev. 2018; 4: 45.
PubMed
P.256 掲載の参考文献
1) 日本呼吸器学会咳嗽・喀痰の診療ガイドライン2019作成委員会, 編. 咳嗽・喀痰の診療ガイドライン 2019.東京: メディカルレビュー社; 2019.
 
2) Greenberg SD, Ainsworth JZ. Comparative morphology of chronic bronchitis and chronic sinusitis, with discussion of "Sinobronchial" syndrome. South Med J. 1966; 59: 64-74.
PubMed
3) 三上理一郎, 工藤翔二, 市村恵一, 他. 副鼻腔気管支症候群の臨床-びまん性汎細気管支炎との関連-. 日本医事新報. 1979; 2892: 3-12.
 
4) Fujimura M, Abo M, Ogawa H, et al. Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology. 2005; 10: 201-7.
PubMed
5) 西 耕一. 副鼻腔気管支症候群. In: 藤村政樹, 編. 慢性咳嗽を診る. 2002. p.135-49.
 
6) 日本咳嗽学会, 編. 専門医のための遷延性・慢性咳嗽の診断と治療に関する指針2021年版. 金沢: 前田書店; 2021.
 
7) 工藤翔二. びまん性汎細気管支炎にたいするマクロライド系抗生剤の少量長期間投与の臨床効果. 日胸疾患会誌. 1984; 22(増刊): 254.
 
8) Kono C, Yamaguchi T, Yamada Y, et al. Historical changes in epidemiology of diffuse panbronchiolitis. Sarcoidosis Vasc Diffuse Lung Dis. 2012; 29: 19-25.
 
9) 山中 晃, 斎木茂樹, 田村静夫, 他. 慢性気管支閉塞性疾患の問題点特に瀰漫性汎細気管支炎. 内科. 1969; 23: 442-51.
 
10) Sugiyama Y, Kudoh S, Maeda H, et al. Analysis of HLA antigens in patients with diffuse panbronchiolitis. Am Rev Respir Dis. 1990; 141: 1459-62.
PubMed
11) 斎木茂樹, 山中 晃. 病理像. In: 谷本晋一, 田村昌士, 編. びまん性汎細気管支炎とその類縁疾患. 東京: 南工堂; 1995.p. 5-11.
 
12) Azuma A, Kudoh S. Diffuse panbronchiolitis in East Asia. Respirology. 2006; 11: 249-61.
PubMed
13) 工藤翔二. Master's Lectures マクロライド少量長期療法の発見とその後の展開. Modern Media. 2016; 62: 16-23.
 
14) 西 耕一, 明 茂治, 大家他喜雄, 他. 副鼻腔気管支症候群(SBS)患者の粘液線毛輸送能に対するエリスロマイシン療法の効果. 日胸疾患会誌. 1993; 31: 1367-76.
 
15) 西 耕一, 水口雅之, 橘 秀樹, 他. 副鼻腔気管支症候群の臨床所見と粘液線毛輸送能に対するクラリスロマイシンの効果. 日胸疾患会誌. 1995; 33: 1392-400.
 
16) Kudoh S, Azuma A, Yamamoto M, et al. Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med. 1998; 157: 1829-32.
PubMed
17) 門田淳一. マクロライド研究の新展開. びまん性汎細気管支炎・気管支拡張症. Respiratory Medical Research. 2014; 2: 240-4.
 
P.267 掲載の参考文献
1) Jennette JC. Overview of the 2012 revised International Chapel Hill Consensus Conference nomenclature of vasculitides. Clin Exp Nephrol. 2013; 17: 603-6.
 
2) 難病情報センターHP. <https://www.nanbyou.or.jp/wp-content/uploads/upload_files/koufu20191.pdf>
 
3) Wechsler ME, Drazen JM. Zafirlukast and Churg-Strauss syndrome. Chest. 1999; 116: 266-7.
PubMed
4) Basta F, Mazzuca C, Nucera E, et al. Omalizumab in eosinophilic granulomatosis with polyangiitis: friend or foe? A systematic literature review. Clin Exp Rheumatol. 2020; 38 Suppl 124: 214-20.
PubMed
5) Hoccevar A, Kopac P, Rotar Z, et al. Eosinophilic granulomatosis with polyangiitis evolution during severe eosinophilic asthma treatment with benralizumab. J Allergy Clin Immunol Pract. 2020; 8: 2448-9.
PubMed
6) Vaglio A, Martorana D, Maggiore U, et al. HLA-DRB4 as a genetic risk factor for Churg-Strauss Syndrome. Arthritis Rheum. 2007; 56: 3159-66.
PubMed
7) Wieczorek S, Hellmich B, Gross WL, et al. Associations of Churg-Strauss syndrome with the HLA-DRB1 locus, and relationship to the genetics of antineutrophil cytoplasmic antibody-associated vasculitides. Arthritis Rheum. 2008; 58: 329-30.
 
8) Wieczorek S, Hellmich B, Arning L, et al. Functionally relevant variations of the interleukin-10 gene associated with antineutrophil cytoplasmic antibody-negative Churg-Strauss Syndrome, but not with Wegener's granulomatosis. Arthritis Rheum. 2008; 58: 1839-48.
 
9) Alberici F, Bonatti F, Adorni A, et al. FCGR3B polymorphism predicts relapse risk in eosinophilic granulomatosis with polyangiitis. Rheumatogy. 2020; 59: 3563-6.
 
10) Tsurikisawa N, Morita S, Tsuburai T, et al. Familial Churg-Strauss syndrome in two sisters. Chest. 2007; 131: 592-4.
PubMed
11) Ueki Y, Oshikata C, Kaneko T, et al. Familial eosinophilic granulomatosis with polyangiitis in a sister and brother. Intern Med. 2020; 59: 991-5.
 
12) Harmanci K, Anil H, Kocak A, et al. Familial eosinophilic granulomatosis with polyangiitis in a mother and daughter. BMJ Case Rep. 2014; doi: 10. 1136/bcr-2014-206934.
 
13) Berti A, Boukhlal S, Groh M, et al. Eosinophilic granulomatosis with polyangiitis: the multifaceted spectrum of clinical manifestations at different stages of the disease. Expert Review Clin Immunol. 2020; 16: 51-61.
PubMed
14) Tsurikisawa N, Tsuburai T, Saito H, et al. A Retrospective study of bronchial hyperresponsiveness in asthmatic patients prior to the onset of Churg-Strauss syndrome. Allergy Asthma Proc. 2007; 28: 336-43.
 
15) Cottin Y, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis(Churg-Strauss). Eur Respir J. 2016; 48: 1429-41.
 
16) Latorre M, Baldini C, Seccia V, et al. Asthma control and airway inflammation in patients with eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2016; 4: 512-9.
PubMed
17) Berti A, Volcheck GW, Cornec D, et al. Severe/uncontrolled asthma and overall survival in atopic patients with eosinophilic granulomatosis with polyangiitis. Respir Med. 2018; 142: 66-72.
PubMed
18) Beri A, Cornec D, Moura MC, et al. Eosinophilic granulomatosis with polyangiitis: clinical predictors of long-term asthma severity. Chest. 2020; 157: 1086-99.
 
19) Mukherjee M, Thomas SR, Radford K, et al. Sputum antineutrophil cytoplasmic antibodies in serum antineutrophil cytoplasmic antibody-negative eosinophilic granulomatosis with polyangiitis. Am J Respir Crit Care Med. 2019; 199: 158-70.
PubMed
20) Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum. 2005; 52: 2926-35.
PubMed
21) Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med. 2005; 143: 632-8.
PubMed
22) Chang HC, Chou PC, Lai CY, et al. Antineutrophil cytoplasmic antibodies and organ-specific manifestations in eosinophilic granulomatosis with polyangiitis: A systematic review and meta-analysis. J Allergy Clin Immunol Pract. 2021; 9: 445-52.
PubMed
23) Samson M, Puechal X, Devilliers H, et al. Long-term outcomes 118 patients with eosinophilic granulomatosis with polyangiitis(Churg-Strauss syndrome)enrolled in two prospective trial. J Autoimmun. 2013; 43: 60-9.
 
24) Durel CA, Berthiller J, Caboni S, et al. Long-term followup of a multicenter cohort of 101 patients with eosinophilic granulomatosis with polyangiitis(Churg-Strauss). Arthritis Care Res(Hoboken). 2016; 68: 374-87.
PubMed
25) Tsurikisawa N, Oshikata C, Watanabe M, et al. Innate immune response reflects disease activity in eosinophilic granulomatosis with polyangiitis. Clin Exp Allergy. 2018; 48: 1305-16.
PubMed
26) Tsurikisawa N, Oshikata C, Tsuburai T, et al. Th17 cells reflect colon submucosal pathologic changes in active eosinophilic granulomatosis with polyangiitis. BMC Immunol. 2015; 16: 75.
PubMed
27) Raffray L, Guillevin L. Treatment of eosinophilic granulomatosis with polyangiitis: A review. Drugs. 2018; 78: 809-21.
PubMed
28) Kotas ME, Dion J, Van Dyken S, et al. A role for IL-33-activated ILC2s in eosinophilic vasculitis. JCI Insight. 2021 Jun 22; 6(12): e143366.doi: 10.1172/jci.insight. 143366.
 
29) Tsurikisawa N, Saito H, Tsuburai T, et al. Differences in regulatory T cells between Churg-Strauss syndrome and chronic eosinophilic pneumonia with asthma. J Allergy Clin Immunol. 2008; 122: 610-6.
PubMed
30) Tsurikisawa N, Saito H, Oshikata C, et al. An increase of CD83+ dendritic cells ex vivo correlates with increased regulatory T cells in patients with active eosinophilic granulomatosis and polyangiitis. BMC Immunol. 2014; 15: 32-43.
PubMed
31) Lanham JG, Elkon KB, Pusey CD, et al. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine(Baltimore). 1984; 63: 65-81.
 
32) Masi AT, Hunder GG, Lie JT, et al. The American collage of rheumatology 1990 criteria for the classification of Churg-Strauss syndrome(allergic granulomatosis and angitis). Arthritis Rheum. 1990; 33: 1094-100.
 
33) Grayson PC, Ponte C, Suppiah R, et al. 2022 American College of Rheumatology/European alliance of associations for rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Arthritis Rheu. 2022; 1-7.DOI 10. 1002/art. 41982
 
34) Ozaki S. ANCA-associated vasculitis: diagnostic and therapeutic strategy. Allergol Int. 2007; 56: 87-96.
PubMed
35) Silva CI, Muller NL, Fujimoto K, et al. Churg-Strauss syndrome: high resolution CT and pathologic findings. J Thorac Imaging. 2005; 20: 74-80.
PubMed
36) Duran E, Kilic L, Durhan G, et al. Vital corner of diagnostic challenge: eosinophilic granulomatosis with polyangiitis or COVID-19 pneumonia? Ann Rheum Dis. 2020; annrheumdis-2020-218533.
 
37) Hashizume H, Sano Y, Furukawa S, et al. Eosinophilic granulomatosis with polyangiitis mimicking coronavirus disease 2019: a case report. J Eur Acad Dermatol Venereol. 2020; 34: e557-9.
PubMed
38) Schramm MA, Venhoff N, Wagner D, et al. COVID-19 in a severely immunosuppressed patient with life-Threatening eosinophilic granulomatosis with polyangiitis. Front immunol. 2020; 11: 2086.doi: 10. 3389/fimmu. 2020. 02086.
 
39) Guillevin L, Pagnoux C, Seror R, et al. The five-factor score revisited. Assessment of prognosis of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG)Cohort. Medicine. 2011; 90: 19-27.
 
40) Moosig F, Bremer JP, Hellmich B, et al. A vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis(Churg-Strauss, EGPA): monocentric experiences in 150 patients. Ann Rheum Dis. 2013; 72: 1011-7.
PubMed
41) Tsurikisawa N, Oshikata C, Kinoshita A, et al. Long-term prognosis of 121 patients with eosinophilic granulomatosis with polyangiitis in Japan. J Rheumatol. 2017; 44: 1206-15.
 
42) Jardel S, Puechal X, Quellec AL, et al. Mortality in systemic necrotizing vasculitides: A retrospective analysis of the French Vasculitis Study Group registry. Autoimmun Rev. 2018; 17: 653-9.
 
43) Comarmond C, Pagnoux C, Khellaf M, et al. Eosinophilic granulomatosis with polyangiitis(Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort. Arthritis Rheum. 2013; 65: 270-81.
 
44) Doubelt I, Cuthbertson D, Carette S, et al. Clinical manifestations and long-term outcomes of eosinophilic granulomatosis with polyangiitis in North America. ACR Open Rheumatol. 2021; 3: 404-12.
PubMed
45) Samson M, Puechal X, et al. Mononeuritis multiplex predicts the need for immunosuppressive or immunomodulatory drugs for EGPA, PAN and MPA patients without poor-prognosis factors. Autoimmunity Rev. 2014; 13: 945-53.
PubMed
46) Springer JM, Kalot MA, Husainat NM, et al. Eosinophilic granulomatosis with polyangiitis: A systematic review and meta-analysis of test accuracy and benefits and harms of common treatments. ACR Open Rheumatol. 2021; 3: 101-10.
PubMed
47) Tsurikisawa N, Taniguchi M, Saito H, et al. Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin. Annals Allergy Asthma Immunol. 2004; 92: 80-7.
 
48) Tsurikisawa N, Saito H, Oshikata C, et al. High-dose intravenous immunoglobulin treatment increases regulatory T cells in patients with eosinophilic granulomatosis with polyangiitis. J Rheumatol. 2012; 39: 1019-25.
PubMed
49) Tsurikisawa N, Saito H, Oshikata C, et al. High-dose intravenous immunoglobulin therapy for eosinophilic granulomatosis with polyangiitis. Clinical and Translational Allergy. 2014; 4: 38.
PubMed
50) Thiel J, Troilo A, Salzer U, et al. Rituximab as induction therapy in eosinophilic granulomatosis with polyangiitis refractory to conventional immunosuppressive treatment: A 36-month follow-up analysis. J Allergy Clin Immunol Pract. 2017; 5: 1556-63.
PubMed
51) Fanouriakids A, Kougkas N, Vassilopoulos D, et al. Rituximab for eosinophilic granulomatosis with polyangiitis with severe vasculitic neuropathy: Case report and review of current clinical evidence. Semin Arthritis Rheum. 2015; 45: 60-6.
PubMed
52) Akiyama M, Kaneko Y, Takeuchi T. Rituximab for the treatment of eosinophilic granulomatosis with polyangiitis: A systemic literature review. Autoimmun Rev. 2021; 20: 102737.
 
53) Teixeira V, Mohammad AJ, Jones RB, et al. Efficacy and safety of rituximab in the treatment of eosinophilic granulomatosis with polyangiitis. RMD Open. 2019; 5: e000905.
PubMed
54) Moura MC, Berti A, Keogh KA, et al. Asthma control in eosinophilic granulomatosis with polyangiitis treated with rituximab. Clin Rheumatology. 2020; 39: 1581-90.
 
55) Trivioli G, Terrier B, Vaglio A. Eosinophilic granulomatosis with polyangiitis: understanding the disease and its management. Rheumatology(Oxford). 2020; 59(Suppl 3): iii84-94.
 
56) Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis. N Engl J Med. 2017; 376: 1921-32.
 
57) Ennis D, Lee JK, Pagnoux C, et al. Mepolizumab for the treatment of eosinophilic granulomatosis with polyangiitis. Expert Opinion Biological Therapy. 2019; 19: 617-30.
 
58) Ueno M, Miyagawa I, Nakano K, et al. Effectiveness and safety of mepolizumab in combination with corticosteroids in patients with eosinophilic granulomatosis with polyangiitis. Arthritis Res Ther. 2021; 23: 86-94
 
59) Kitamura N, Hamaguchi M, Nishihara M. The effects of mepolizumab on peripheral circulation and neurological symptoms in eosinophilic granulomatosis with polyangiitis(EGPA)patients. Allergol Int. 2021; 70: 148-9.
PubMed
60) Rios-Garces R, Prieto-Gonzalez S, Hernandez-Rodriguez J, et al. Response to mepolizumab according to disease manifestations in patients with eosinophilic granulomatosis with polyangiitis. Eur J Intern Med. 2021; S0953-6205(21)00294-6.doi: 10. 1016/j. ejim. 2021.08.021.
 
61) Tsurikisawa N, Oshikata C, Watanabe M, et al. Clinical features of patients with active eosinophilic granulomatosis with polyangiitis successfully treated with mepolizumab. Int Arch Allergy Immunol. 2021; 1-13.doi: 10. 1159/000514505.
 
62) Canzian A, Venhoff N, Urban ML, et al. Use of biologics to treat relapsing and/or refractory eosinophilic granulomatosis with polyangiitis: data from a European Collaborative Study. Arthritis Rheumatol. 2021; 73: 498-503.
PubMed
63) Vultaggio A, Nencini F, Bormioli S, et al. Low-dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis. Allergy Asthma Immunol Res. 2020; 12: 885-93.
PubMed
64) Bettiol A, Urban ML, Dagna L, et al. Mepolizumab for eosinophilic granulomatosis with polyangiitis: A European Multicenter Observational Study. Arthritis Rheum. 2022; 74: 295-306.
 
65) Jachiet M, Samson M, Cottin V, et al. Anti-IgE monoclonal antibody(omalizumab)in refractory and relapsing eosinophilic granulomatosis with polyangiitis(Churg-Strauss): data on seventeen patients. Arthritis Rheumatol. 2016; 68: 2274-82.
PubMed
66) Guntur VP, Manka LA, Denson JL, et al. Benralizumab as a steroid-sparing treatment option in eosinophilic granulomatosis with polyangiitis. Allergy Clin Immunol Pract. 2021; 9: 1186-93.e1.
 
67) Carrillo-Martin I, Abril A, Donaldson AM, et al. An alternative approach against eosinophils for the treatment of eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol Pract. 2020; 8: 2079-80.
PubMed
68) Galant-Swafford J, Geng B, Leibel S, et al. Two pediatric cases of ANCA-negative eosinophilic granulomatosis with polyangiitis successfully treated with dupilumab. Allergy Clin Immunol Pract. 2020; 10: 3643-6.e1.
 
69) Kent BD, d'Ancona G, Fernandes M, et al. Oral corticosteroid-sparing effects of reslizumab in the treatment of eosinophilic granulomatosis with polyangiitis. ERJ Open Res. 2020; 6: 00311-2019.
PubMed
70) Tsurikisawa N, Saito H, Oshikata C, et al. Decreases in the numbers of peripheral blood regulatory T cells, and increases in the levels of memory and activated B cells, in patients with active eosinophilic granulomatosis and polyangiitis. J Clin Immunol. 2013; 33: 965-76.
PubMed
P.281 掲載の参考文献
1) 平成30年厚生科学審議会疾病対策部会. リウマチ等対策委員会報告書. 2018年11月. <https://www.mhlw.go.jp/stf/shingi2/0000172968_00003.html>
 
2) Yamanaka H, Sugiyama N, Inoue E, et al. Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort(I). Mod Rheumatol. 2014; 24: 33-40.
PubMed
3) Murano E, Hosako-Naito Y, Tayama N, et al. Bamboo node: primary vocal fold lesion as evidence of autoimmune disease. J Voice. 2001; 15: 441-50.
PubMed
4) Kadura S, Raghu G. Rheumatoid arthritis-interstitial lung disease: manifestations and current concepts in pathogenesis and management. Eur Respir Rev. 2021; 30: 210011.
PubMed
5) Rudrappa M, Kokatnur L, Shah S. Case report: Upper airway obstruction due to rheumatoid arthritis. F1000Res. 2020; 9: 119.
PubMed
6) Wiater R, Hakansson KEJ, Ulrik CS. A causal relationship between rheumatoid arthritis and bronchiectasis? A systematic review and meta-analysis. Chron Respir Dis. 2021; 18: 1479973121994565.
PubMed
7) Esposito AJ, Chu SG, Madan R, et al. Thoracic manifestations of rheumatoid arthritis. Clin Chest Med. 2019; 40: 545-60.
PubMed
8) 永山雅晴, 千田金吾, 豊嶋幹生. 慢性関節リウマチに先行した濾胞性細気管支炎の1例. 日呼吸会誌. 2002; 40: 236-40.
Medical*Online
9) Devouassoux G, Cottin V, Liote H, et al. Characterisation of severe obliterative bronchiolitis in rheumatoid arthritis. Eur Respir J. 2009; 33: 1053-61.
PubMed
10) Lin E, Limper AH, Moua T. Obliterative bronchiolitis associated with rheumatoid arthritis: analysis of a single-center case series. BMC Pulm Med. 2018; 18: 105.
PubMed
11) Mori S, Koga Y, Sugimoto M. Different risk factors between interstitial lung disease and airway disease in rheumatoid arthritis. Respir Med. 2012; 106: 1591-9.
PubMed
12) Schwemmle C, Kreipe HH, Witte T, et al. Bamboo nodes associated with mixed connective tissue disease as a cause of hoarseness. Rheumatol Int. 2013; 33: 777-81.
PubMed
13) Mathieu A, Cauli A, Pala R, et al. Tracheo-bronchial mucociliary clearance in patients-with primary and secondary Sjogren's syndrome. Scand J Rheumatol. 1995; 24: 300-4.
PubMed
14) Lee AS, Scofield RH, Hammitt KM, et al. Consensus Expert Panel(CEP)members. Consensus guidelines for evaluation and management of pulmonary disease in Sjogren's. Chest. 2021; 159: 683-98.
 
15) Flament T, Bigot A, Chaigne B, et al. Pulmonary manifestations of Sjogren's syndrome. Eur Respir Rev. 2016; 25: 110-23.
PubMed
16) Soto-Cardenas MJ, Perez-De-Lis M, Bove A, et al. Bronchiectasis in primary Sjogren's syndrome: prevalence and clinical significance. Clin Exp Rheumatol. 2010; 28: 647-53.
PubMed
17) 厚生労働省 難治性疾患政策研究事業 難治性血管炎に関する調査研究班血管炎症候群の診療ガイドライン(2017 年改訂版). 2018年6月.
 
18) Hughes JP, Stovin PG. Segmental pulmonary artery aneurysms with peripheral venous thrombosis. Br J Dis Chest. 1959; 53: 19-27.
 
19) Emad Y, Ragab Y, Robinson C, et al. Pulmonary vasculitis in Hughes-Stovin syndrome(HSS): a reference atlas and computed tomography pulmonary angiography guide-a report by the HSS International Study Group. Clin Rheumatol. 2021; 40: 4993-5008.
 
20) Sanduleanu S, Jansen TLTA. Hughes-Stovin syndrome(HSS): current status and future perspectives. Clin Rheumatol. 2021; 40: 4787-9.
PubMed
21) Brookes GB. Pharyngeal stenosis in Behcet's syndrome. The first reported case. Arch Otolaryngol. 1983; 109: 338-40.
PubMed
22) Witt C, John M, Martin H, et al. Behet's syndrome with pulmonary involvement combined therapy for endobronchial stenosis using neodym-YAG laser, balloon dilation and immunosuppression. Respiration. 1996; 63: 195-8.
 
23) Wang X, Wan J, Zhao L, et al. IgG4-related disease with tracheobronchial miliary nodules and asthma: a case report and review of the literature. BMC Pulm Med. 2019; 19: 191.
 
24) Saraya T, Ohkuma K, Fujiwara M, et al. Clinical characterization of 52 patients with immunoglobulin G4-related disease in a single tertiary center in Japan: Special reference to lung disease in thoracic high-resolution computed tomography. Respir Med. 2017; 132: 62-7.
 
25) Shimizu J, Yamano Y, Kawahata K, et al. Nationwide cross-sectional survey of patients with relapsing polychondritis in 2019 demonstrates reduction of airway involvement compared with that in 2009.Sci Rep. 2022; 12: 465
PubMed
26) Trentham DE, Le CH. Relapsing polychondritis. Ann Intern Med. 1998; 129: 114-22.
PubMed
27) Shimizu Y, Kamiyoshihara M, Okajo J, et al. Tracheobronchial stenosis evaluated by inspiratory and expiratory three-dimensional computed tomography and impulse oscillation with three-dimensional color imaging in a patient with relapsing polychondritis. J Biol Regul Homeost Agents. 2014; 28: 325-31.
 
28) Martin L, Edworthy SM, Ryan JP, et al. Upper airway disease in systemic lupus erythematosus: a report of 4 cases and a review of the literature. J Rheumatol. 1992; 19: 1186-90.
 
29) Di Bartolomeo S, Alunno A, Carubbi F. Respiratory manifestations in systemic lupus Erythematosus. Pharmaceuticals(Basel). 2021; 14: 276.
PubMed
30) Richeldi L, Scholand MB, Lynch DA, et al. Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med. 2021; 203: 211-20.
PubMed
31) Hvidtfeldt M, Pulga A, Hostrup M, et al. Bronchoscopic mucosal cryobiopsies as a method for studying airway disease. Clin Exp Allergy. 2019; 49: 27-34.
PubMed
32) Arafah MA, Raddaoui E, Kassimi FA, et al. Endobronchial biopsy in the final diagnosis of chronic obstructive pulmonary disease and asthma: a clinicopathological study. Ann Saudi Med. 2018; 38: 118-24.
PubMed
33) 立原素子. 気道内で隆起性病変を見た時に-アプローチ方法も含めて-気管支学. 2020; 42: 552-7.
Medical*Online
P.290 掲載の参考文献
1) Hayashi M, Hokari S, Aoki N, et al. A case of bronchiolitis obliterans after living-donor renal transplantation. Respir Investig. 2021; 59: 367-71.
PubMed
2) Lai RS, Chiang AA, Wu MT, et al. Outbreak of bronchiolitis obliterans associated with consumption of Sauropus androgynus in Taiwan. Lancet. 1996; 348: 83-5.
PubMed
3) 大中原研一, 末次隆行, 町田健太, 他. アマメシバによる閉塞性細気管支炎. 呼吸. 2008; 27: 283-8.
Medical*Online
4) 難治性びまん性肺疾患診療の手引き作成委員会. 難治性びまん性肺疾患診療の手引き. 東京: 南江堂; 2017.
 
5) Meyer KC, Raghu G, Verleden GM, et al. An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome. Eur Respir J. 2014; 44: 1479-503.
PubMed
6) Gupta N, Finlay GA, Kotloff RM, et al. Lymphangioleiomyomatosis diagnosis and management: high-resolution chest computed tomography, transbronchial lung biopsy, and pleural disease management. Am J Respir Crit Care Med. 2017; 196: 1337-48.
PubMed
7) McCormack FX, Inoue Y, Moss J, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med. 2011; 364: 1595-606.
PubMed

書評

最近チェックした商品履歴

Loading...